Adipose tissue and insulin secretion in the pathophysiology of obesity and its complications by Belligoli, Anna
 
 
Sede Amministrativa: Università degli Studi di Padova 
 
Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari 
___________________________________________________________________ 
SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE MEDICHE,  
CLINICHE E SPERIMENTALI 
INDIRIZZO: “METODOLOGIA CLINICA, SCIENZE ENDOCRINOLOGICHE E 
DIABETOLOGICHE” 
 
CICLO: XXVIII 
ADIPOSE TISSUE AND INSULIN SECRETION IN THE 
PATHOPHYSIOLOGY OF OBESITY AND ITS 
COMPLICATIONS 
 
Direttore della Scuola: Ch.mo Prof. Gaetano Thiene 
Coordinatore d’indirizzo: Ch.mo Prof. Roberto Vettor 
Supervisori: Chiar.mo Prof. Roberto Vettor; Dott.ssa G. Milan 
 
                Dottoranda: Anna Belligoli 
          
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
INDEX 
 
Abstract                                                                                                          pg 5 
Riassunto                                                                                                       pg 7 
1. Introduction                                                                                             pg 11 
1.1. Obesity Definition and Classification                                              pg 12 
1.2. Obesity Epidemiology                                                                      pg 14 
1.3. Obesity Complication                                                                      pg 15 
1.3.1. Diabesity                                                                                pg 16 
1.4. Obesity Therapy                                                                               pg 18 
1.4.1. Pharmacological Therapy                                                      pg 19 
1.4.2. Bariatric Surgery                                                                   pg 20 
1.4.2.1. Laparoscopic Adjustable Gastric Banding                pg 22 
1.4.2.2. Laparoscopic Sleeve Gastrectomy (LSG)                 pg 22 
1.4.2.3. Roux en Y Gastric Bypass (RYGB)                          pg 24 
1.4.2.4. Hypoglyceamia after bariatric surgery                      pg 25 
2. Adipose Tissue (AT)                                                                               pg 26 
2.1. Subcutaneous and Visceral Adipose Tissue                                     pg 28 
2.2. Adipose Tissue Endocrine Function                                                pg 29 
2.2.1. Leptin                                                                                     pg 30 
2.2.2. IL-6                                                                                        pg 32 
2.2.3. TNF-α                                                                                    pg 33 
2.3. Adipose Tissue Stem Cells (ASCs)                                                 pg 34 
2.4. Adipose Tissue Angiogenesis and Hypoxia                                     pg 37 
3. Aims                                                                                                        pg 43 
3.1. Aims (1)                                                                                           pg 43 
3.2. Aims (2)                                                                                           pg 44 
4. Material and Methods                                                                             pg 45 
4.1. Material and Methods (1)                                                                pg 45 
4.1.1. Ethic Statements                                                                    pg 45 
3 
4.1.2. Human Subjects                                                                                              pg 45 
4.1.3. Histological and Immunohistochemical Analysis                                          pg 46 
4.1.3.1. Adipose Tissue Capillarization                                                           pg 46 
4.1.3.2. Adipocyte Size                                                                                    pg 46 
4.1.4. Human Adipocytes Primary Cultures and Flow Cytometry Analysis            pg 46 
4.1.4.1. Stromal Vascular Fraction Extraction                                                 pg 46 
4.1.4.2. Flow Cytometry Analysis                                                                   pg 47 
4.1.4.3. Human Adipocyte Primary Cultures                                                  pg 47 
4.1.5. RNA Extraction and RT-Real time PCR                                                       pg 48 
4.1.6. Statistical Analysis                                                                                        pg 49 
4.2. Material and Methods (2)                                                                                        pg 49 
4.2.1. Ethic Statements                                                                                           pg 49 
4.2.2. Patients                                                                                                         pg 49 
4.2.3. Statistical Analysis                                                                                       pg 50 
5. Results                                                                                                                           pg 51 
5.1. Results (1)                                                                                                              pg 51 
5.1.1. Patients                                                                                                        pg 51  
5.1.1.1. Clinical Evaluation of Obese Patients                                             pg 51 
5.1.1.2. Lean Subjects and Obese Patients After Weight Loss                     pg 53 
5.1.2. Histology and Immunohistochemistry                                                        pg 54 
5.1.2.1. Adipocyte Size                                                                                pg 55 
5.1.2.2. Capillary Density                                                                            pg 56 
5.1.3. Flow Cytofluorimetric Analysis of Stromal Vascular Fraction                  pg 59 
5.1.3.1. Glucose Impairment Early Affects Adipose Stem Cells in Obesity   pg 60 
5.1.3.2. Endothelial Progenitors are progressively altered altered by 
Obesity and Overt Diabetes                                                         pg 65 
5.1.4. In vitro Evaluation of Adipogenic Potential of Stromal Vascular Fraction 
Obtained from Adipose Tissue depots                                                pg 66 
5.1.5. Gene Expression Profile by RT-Real Time PCR                                      pg 69 
5.2. Results (2)                                                                                                          pg 73 
5.2.1. Anthropometric and Metabolic Parameters one year after LSG             pg 73 
5.2.2. Prevalence of OGTT-related Hypoglycaemia one year after LSG...........pg 74 
4 
5.2.3. Anthropometric and Metabolic Parameters, before and one year after 
LSG, in Patients With and Without Hypoglycaemic Events               pg 75 
5.2.4. Predictors of Hypoglycaemic Events before Surgery                         pg 78 
6. Discussion                                                                                                            pg 79 
6.1. Discussion (1)                                                                                               pg 79 
6.2. Discussion (2)                                                                                               pg 85 
7. References                                                                                                            pg 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
ABSTRACT 
Type 2 diabetis mellitus (T2DM) and obesity are global health care problems that are closely 
linked together. The precise mechanisms linking the two conditions remain unclear. Indeed, 
while the close relationship between T2DM and weight gain is well established, not all obese 
subjects are diabetic and this paradox is still unexplained. Impaired tissue perfusion has been 
proposed as one of the common metabolic defects, but little is known about adipose tissue (AT) 
microangiopathy and its possible role in T2DM. In animal models of obesity and diabetes, 
expanding AT microvasculature appears structurally altered and the angiogenetic potential of 
adipose derived stem cells impaired. 
Several studies, in humans, suggest that obesity leads to an impaired angiogenesis and AT 
hypoxia, inducing an inflammatory and a profibrotic response that plays a pivotal role in the 
pathogenesis of metabolic complications related to weight gain, first of all insulin resistance 
and diabetes. Moreover, from a pathophysiological point of view it is well established that 
dysfunctional visceral adipose tissue (VAT) is one of the major determinants of metabolic 
complications of obesity, while subcutaneous depots has been considered metabolically 
healthy. Nevertheless it could be hypothesized that in the progress of obesity through the 
metabolic impairment, SAT could become dysfunctional as VAT.  
On the basis of these data, we planned to study both subcutaneous and visceral adipose tissue 
in terms of adipocytes size, capillary density, adipose tissue stem cells (ASCs), endotelial 
precursor of AT and adipogenic potential, in obese subjects compared to lean subjects and in 
obese patients with a different glyceamic profile. 
We collected subcutaneous (SAT) and/or visceral (VAT) adipose tissue (AT) from 249 patients 
divided in 5 different groups: 18 lean normal weight and normoglycemic subjects (18.5 < BMI 
< 24,9 kg/m2) as control group, 68 normoglycemic obese subjects (ob N), 65 pre-diabetic 
obese subjects (ob pre-T2DM), 57 diabetic obese subjects (ob T2DM) and 41obese patients 
after underwent to a relevant weight loss (ob WL), corresponding to at least 10% of body 
weight. In different representative subgroups of these samples we performed: 1) 
immunohistochemical analysis to evaluate the morphometry of adipocyte and capillary density; 
2) flow cytofluorimetric analysis of stromal vascular fraction (SVF) in order to quantify 
adipose tissue stem cells (ASCs), defined as CD45-CD34+CD31-, and endothelial precursors 
cells (EPs) defined as CD45-CD34+CD31+; 3) in vitro culture of ASCs obtained from SVF, in 
order to estimate the adipogenic potential in the different groups and  different depot of AT; 4) 
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gene expression profile by RT-Real Time PCR of PPRγ, Leptin, VEGFA, VEGF2, HIF1α to 
correlate their expression with previous findings. 
Our study confirm that obese AT is less vascularized than lean AT but T2DM does not 
represent an aggravating factor to the vascular reduction already present in obesity. On the 
contrary, T2DM and also prediabetic condition are able to further modify AT architecture, 
remodeling mature adipocyte size and adipogenic potential mediated by ASCs, importantly 
reducing AT hyperplastic growth capacity. Moreover our results allow us to assume that 
primum movens in development of T2DM must be searched in AT architecture and that both 
depots, SAT and VAT, play a pivotal role in the development of this disease. 
Furthermore, considering the continuous increase in bariatric procedures to treat both weigh 
gain and associated co-morbidities, we plan to evaluate the effects of laparoscopic sleeve 
gastrectomy (LSG) after one year. Indeed, whereas the beneficial effects of this bariatric 
procedure are well known, side effects are lesser known. In particular, postprandial 
hypoglycaemia is a well described side effect after RYGB, but few data are available for LSG.. 
We enrolled a total of 197 consecutive non-diabetic morbidly obese who underwent to LSG in 
our Center for the Study and the Integrated Treatment of Obesity (Ce.S.I.T.O.). All patients 
were studied 12 months before and after LSG and, anthropometrics parameters, medical 
history, clinical examination, complete blood count and complete metabolic panel including a 
3- hour OGTT, were collected. 
One year after LSG, all patients had a significant reduction in weight and BMI, a significant 
improvement in glucose and insulin profile, and a significant decrease in inflammatory 
markers. We found an high incidence of severe hypoglycaemia (32,8%) after a provocative test 
(OGTT). Patients with hypoglycaemic events had a lower weight and BMI and a greater 
%EBML after LSG. compared to patients without hypoglycemic events. Hypoglycaemia was 
more frequent in patients having lower age, lower fasting blood glucose levels and higher 
triglycerides levels before LSG.  
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RIASSUNTO 
L’obesità e il diabete mellito tipo 2 (T2DM) sono due patologie strettamente correlate tra loro 
e, insieme, rappresentano una delle maggiori emergenze sanitarie a livello mondiale. I 
meccanismi fisiopatologici che legano le due patologie, non sono ancora stati completamente 
spiegati. Infatti, mentre sono abbastanza note le alterazioni che portano dall’aumento del peso 
corporeo alla comparsa di T2DM, meno noti sono i motivi per cui non tutti i pazienti obesi 
sviluppano la patologia diabetica. Per spiegare tale paradosso, alcuni studi si sono concentrati 
sulla possibile diversa capacità di espansione del tessuto adiposo (TA). Come tutti i tessuti, 
anche il TA, per poter espandersi, necessita di un’adeguata consensuale vascolarizzazione. E’ 
stato ipotizzato che un’alterata angiogenesi durante l’espansione del TA in alcuni soggetti, e la 
presenza di un danno a livello del microcircolo dello stesso TA, possano influire negativamente 
sul peggioramento del profilo glicemico. In alcuni modelli di animali, affetti da diabete e 
obesità, si sono evidenziate alterazioni a carico del microcircolo del TA e a carico del 
potenziale adipogenico. Consensualmente, alcuni studi sul TA dell’uomo, hanno suggerito che 
l’obesità porta ad una alterazione dell’angiogenesi a livello del TA con contemporanea 
comparsa di uno stato ipossico a sua volta responsabile della risposta infiammatoria e 
profibrotica. Infiammazione e fibrosi, hanno un ruolo fondamentale nello sviluppo 
dell’insulino-resistenza e quindi del T2DM. Inoltre, è noto che il tessuto adiposo viscerale 
(VAT) rappresenta il deposito di TA con maggior grado di infiammazione, mentre il tessuto 
adiposo sottocutaneo (SAT) è considerato un tessuto meno infiammato e in grado di avere un 
ruolo protettivo nei confronti dello sviluppo delle patologie metaboliche. Nonostante ciò, è 
possibile ipotizzare che con l’aumento progressivo del peso corporeo anche il SAT acquisisca 
caratteristiche disfunzionali come il VAT. 
Sulla base di questi presupposti, abbiamo deciso di analizzare le possibili variazioni in termini 
di morfologia, di densità capillare, di quantità di precursori adipogenici, di potenziale 
adipogenetico sia nel SAT che nel VAT di pazienti obesi e di pazienti normopeso 
normoglicemici. Inoltre, tra i pazienti obesi, sulla base delle caratteristiche cliniche e 
biochimiche, abbiamo selezionato coloro che erano normoglicemici (ob N), pre-diabetici (ob 
pre-T2DM) e diabetici (ob T2DM). 
Sono, quindi, stati raccolti campioni di SAT e/o il VAT da 249 pazienti divisi nei 4 gruppi sopra 
descritti: 18 pazienti normopeso e normoglicemici (18.5 < BMI < 24,9 kg/m2), 68 ob N, 65 ob 
pre-T2DM e 57 ob T2DM. Abbiamo, inoltre, avuto l’opportunità di analizzare il SAT di 41 
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pazienti obesi dopo significativo calo ponderale (ob WL). I campioni di TA sono stati studiati 
(1) mediante analisi immunocitochimica, al fine di valutare la morfologia degli adipociti e la 
densità capillare, (2) mediante analisi citofluorimetrica della frazione vasculo stromale (FVS) 
per quantificare la presenza di precursori adipocitari (CD45-CD34+CD31-) e di precursori 
endoteliali (CD45-CD34+CD31+), (3) attraverso la coltura dei preadipociti estratti dalla FVS, 
per valutare il potenziale adipogenetico; (4) mediante espressione genica di leptina, PPRγ, 
VEGFA, VEGF2 e HIF1-α. 
L’analisi dei nostri dati ci ha permesso di confermare che il tessuto adiposo dei soggetti obesi è 
significativamente meno vascolarizzato, sia nel SAT che, dato ad oggi non noto, nel VAT, 
rispetto al tessuto adiposo dei soggetti magri. Diversamente da quanto ipotizzato, la presenza di 
un alterato profilo glicemico, come quello presente nel pre-diabete, o la presenza di un diabete 
franco, non peggiorano ulteriormente la vascolarizzazione del TA, né nel SAT, né nel VAT. Ciò 
che si modifica in maniera significativa e precoce è l’architettura del TA. Infatti, già nei 
pazienti ob pre-T2DM e, anche nei pz ob T2DM, abbiamo osservato un progressivo aumento 
del diametro degli adipociti. Inoltre, nel TA dei pazienti con alterato profilo glicemico abbiamo 
osservato una significativa riduzione sia nella percentuale dei preadipociti presenti nella FVS 
sia nella loro capacità di differenziare in vitro. Questi dati ci permettono di ipotizzare che il TA 
dei pazienti con alterato profilo glicemico cresce maggiormente per ipertrofia che per 
iperplasia e che il ”primum movens” nello sviluppo della patologia diabetica è da ricercare 
nelle modificazioni a carico della cellula adiposa più che nelle modificazioni del microcircolo 
del tessuto adiposo sia nel VAT ma, anche nel SAT. 
Inoltre, considerando il progressivo incremento nell’utilizzo della chirurgia bariatrica per 
trattare sia l’aumento di peso ma anche le complicanze metaboliche a esso correlate, è stato 
eseguito uno studio sugli effetti della sleeve gastrectomy per via laparoscopica (LSG) a 
distanza di un anno dall’intervento.  Mentre gli effetti positivi di questa procedura chirurgica 
sono ormai noti, meno noti sono gli effetti collaterali; in particolare, l’ipoglicemia post 
prandiale è stata ben descritta dopo intervento di by pass gastrico ma resta ancor poco indagata 
dopo intervento di LSG. Abbiamo, pertanto, reclutato 197 pazienti obesi non diabetici 
sottoposti a LSG e li abbiamo studiati prima e a distanza di un anno dall’intervento bariatrico. 
In tutti i pazienti è stata raccolta la storia clinica, è stato eseguito esame obiettivo e sono stati 
eseguiti gli esami bioumorali comprensivi di screening endocrino-metabolico completo, 
incluso OGTT prolungato a 180 minuti, e dosaggio delle citochine infiammatorie. Un anno 
10 
dopo l’intervento, tutti i pazienti hanno avuto una significativa riduzione del peso corporeo e 
del BMI, un significativo miglioramento dei parametri metabolici, compreso il profilo 
glicemico e insulinemico, e una significativa riduzione delle citochine infiammatorie. Il 32,8% 
dei pazienti ha sviluppato un’ipoglicemia severa dopo test provocativo (OGTT). I pazienti con 
ipoglicemie hanno mostrato un peso e un BMI significativamente minore rispetto ai pazienti 
che non hanno sviluppato ipoglicemia e una percentuale di perdita di BMI significativamente 
maggiore. L’ipoglicemia si è dimostrata essere più frequente in quei pazienti che, prima 
dell’intervento, erano più giovani, con un peso e un BMI inferiore e con livelli di 
trigliceridemia superiori ai pazienti che non avevano sviluppato ipoglicemie dopo LSG.  
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1. INTRODUCTION 
 
Worldwide obesity is doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and 
older, were overweight. Of these over 600 million were obese. Most of the world's population 
live in countries where overweight and obesity kills more people than underweight (WHO, 
2016). The WHO world health statistics report in 2015 shows that in the European region the 
overall obesity rate among adults is 21.5% in males and 24.5% in females. The same report 
states that the prevalence for overweight among children under the age of 5 is 12.4% (WHO, 
2015) 
The impact of obesity on morbidity, mortality and health care cost is profound. Overweight and 
obesity are major risk factors for a number of chronic diseases including diabetes, 
cardiovascular diseases and cancer and, in Europe, is responsible of 6% of health assistance 
cost and it causes 1 million deaths per year (WHO, 2006). Obesity is not just a health issue, but 
a social one as well: it impacts the economical and social system, provoking a decrease in 
productivity (it must be noticed that in the last 50 years young obeses has widely increased), an 
increase of direct and indirect healt-assistence costs and finally social isolation especially 
among young people in Western countries. 
In the recent years, given the large number of people suffering from obesity, exciting advances 
have occurred in all 3 modalities used to treat obesity: lifestyle intervention, pharmacotherapy, 
and weight-loss procedures including bariatric surgery (Garvey WT, 2013). In particular, 
bariatric surgery, has continued to increase in recent years, and over 340.000 procedures were 
performed in the world in 2011 (Buchwald H., 2013). New surgical procedures have been 
developed and refined and aren't known al the long-term effects. 
Moreover, the major disease associated to obesity is type 2 diabetes mellitus (T2DM). It is 
estimated that about 90% of T2DM is attributable to excess weight (Hossain P, 2007), but the 
precise mechanisms linking the two conditions remain unclear. Converging data suggest that an 
impaired function of adipose tissue (AT) could play a pivotal role in T2DM development but 
lot of mechanisms underlying AT dysfunction remain to be established. 
Considering that obesity has become one of the leading causes of disability and death the 
porpoise of our study is to provide a further contribution to knowledge that allow us to better 
understand the pathophysiology of obesity and its complication and the effects of weight loss 
after bariatic surgery. 
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1.1 Obesity Definition and Classification 
Obesity is a chronic disease characterised by an increase of body fat stores. In clinical practice, 
BMI is the parameter commonly use in order to estimate the amount of adipose tissue in human 
body and to classify the severity of obesity. BMI is calculated as measured body weight (kg) 
divided by measured height squared (m
2
). On the base of BMI, it’s possible to stratify the 
population in different categories (Tab. I) where obesity is defined by a BMI ≥ 30 kg/m2. 
 
Definition Western BMI 
 
(Kg/m
2
) 
Class Asiatic BMI 
 
(Kg/m
2
) 
Underweight BMI <18,5   
Normoweight 18, 5 ≤ BMI ≤ 24,9  18,5 ≤ BMI ≤ 22,9 
Overweight 25 <BMI ≤ 29,9  23≤ BMI ≤ 24,9 
Obese 30,0 ≤ BMI ≤ 34,9 I 25≤ BMI≤29,9 
 35,0 ≤ BMI ≤ 39,9 II BMI >30 
 BMI ≥ 40,0 III  
Table I: Western and Southeast Asian population weight classification based on BMI. 
 
Nevertheless BMI is not useful either to distinguish between Fatty Free Mass, Fatty Mass and 
liquid or to describe the adipose tissue distribution. For instance with lower BMI values, Asian 
population has a similar cardiovascular risk (CVR) compared to European population and this 
is the reason why lower BMI cut-off points are applied for some ethnic groups as shown in 
table I.  
That proves that BMI can not be used as a singular tool in order to define obesity and stratify 
the risk of developing cardiovascular and metabolic complications. It is likely necessary to 
define obesity with other parameters and to relate its value with geographical distribution 
(Yusuf S., 2005). 
In 1947 Vague defined a gynoid obesity and an android obesity. In gynoid obesity adipose 
tissue is mainly subcutaneous and it is localized in the buttock and the thighs, in android 
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obesity adipose tissue is mainly localized at the level of abdominal organs causing an increase 
of waist. They have different activities and visceral adipose tissue has a greater correlation with 
development of obesity cardiovascular and metabolic complications rather then subcutaneous 
adipose tissue (Zhu S., 2002).  
The amount of abdominal fat can be assessed by waist circumference which highly correlates 
with intra-abdominal fat content. Following WHO recommendations (1995) waist 
circumference is measured with a tailor-meter at the level of the midpoint of the line which 
connects the inferior border of the lowest rib and the superior border of ilium crest.  
The most recent International Diabetes Federation (IDF) consensus defined central obesity 
(also known as visceral, android, apple-shaped or upper body obesity) in Euripides as a WC of 
≥ 94 cm in men and ≥ 80 cm in non-pregnant women. Lower cut-off points for central obesity 
are proposed for different ethnic groups. 
Therefore, in clinical practice, to assess the risks associated with being overweight or obese, is 
necessary to considered both BMI and WC as shown in Table II (NICE guidelines, 2006). 
 
BMI classification Waist circumference 
 Low Hight Very high 
Overweight No increased risk Increased risk High risk 
Obesity Increased risk High risk Very high risk 
For men, waist circumference of less than 94 cm is low, 94–102 cm is high and 
more than 102 cm is very high. 
For women, waist circumference of less than 80 cm is low, 80–88 cm is high and 
more than 88 cm is very high 
 
Table II. Base assessment of the health risks associated with being overweight or obese in adults on 
BMI and waist circumference 
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1.2 Obesity Epidemiology  
For thousands of years obesity was rarely seen (Haslam D., 2007).  It was not until the 20th 
century that it became common, so much so that in 1997 the World Health Organization 
(WHO) formally recognized obesity as a global epidemic (Caballero B., 2007). Once 
considered a problem only of high-income countries, obesity rates are rising worldwide. The 
transfer of Western eating habits from more developed countries to those in developing 
increases the prevalence of obesity but with an important difference: while in developing 
countries the classes with a major risk of obesity are economically privileged because wealth 
and prestige correspond in more food availability, in rich countries the higher level of obesity is 
among deprived groups. The only remaining region of the world where obesity is not common 
is sub-Saharan Africa (Haslam DW., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Age standardized prevalence of obesity in man (A) and woman (B) age 18 years and over, 2014 
 
A
B
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According with the last report of WHO, in 2014,  39% of adults aged 18+ were overweight 
(BMI ≥ 25 kg/m2) (39% of men and 40% of women) and 13% were obese (BMI ≥30 kg/m2) 
(11% of men and 15% of women).  
Thus, nearly 2 billion adults worldwide were overweight and, of these, more than half a billion 
were obese. The prevalence of overweight and obesity is highest in the Region of the Americas 
(61% overweight or obese in both sexes, and 27% obese) and lowest in the South-East Asia 
Region (22% overweight in both sexes, and 5% obese).  
In the European and Eastern Mediterranean Regions and Region of the Americas, over 50% of 
women are overweight, and in all three regions roughly half of overweight women are obese 
(25% in the European region, 24% in the Eastern Mediterranean Region, 30% in the Region of 
the Americas).  
In all WHO regions, women are more likely to be obese than men. In the African, South-East 
Asia and Eastern Mediterranean regions,, women have roughly double the obesity prevalence 
of men (adapted from WHO 2014) (Figure 1). 
 
 
1.3 Obesity Complications 
The development of obesity is correlated with increasing incidence of diseases affecting several 
organs and systems of human body, which may all be considered as complications of obesity. 
The increase of body weight and the condition of low grade chronic inflammation, present in 
the most of obese subjects, lead to alterations of several organs and tissues. 
Common alterations and dysfunction in obese individuals are: 
- development of a state of insulin-resistance and type 2 diabetes; 
- development of hypertension and dyslipidemia; 
- promotion of the atherosclerotic process; 
- development of a pro-thrombotic state; 
- immunological alterations, susceptibility to the development of inflammatory and 
autoimmune diseases; 
 
In table III all the main diseases and alterations connected to obesity are described. 
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Table III: Main obesity complications 
1.3.1 Diabesity 
T2DM and obesity are global health care problems that are closely linked together. The concept 
of diabesity (obesity-T2DM) emerges by the estimation that about 90% of T2DM is attributable 
Organ/System Complication 
Cardiovascular System 
- Hypertension 
- Ischemic Cardiomyopathy 
- Heart Failure 
- Pulmonary Heart Disease 
- Chronic Venous Insufficiency 
- Pulmonary Tromboembolism 
- Ictus 
Respiratory System 
- Dyspean at rest or during exercise 
- Obstructive sleeping Apnoea 
- Pickwich Syndrome 
- Pulmonary Hypertension 
- Increased post-surgical risk 
Metabolic-Endocrine System 
- Insulin-resistance, Diabetes Type II 
- Dyslipidemia 
- Metabolic Syndrome 
- PCOS 
- Alterations in reproductive system 
- Hyperuricemia and Gout 
Central Nervous System 
- Mood Alterations 
- Depression 
- Eating Disorders 
Gastrointestinal System 
- GERD 
- Cholelithiasis 
- Abdominal Hernia 
Muscular-skeletal System - Osteoarthritis 
- 2. Discal Hernia 
Urinary System - Urinary Incontinence 
Neoplastic Diseases 
- Breast 
- Ovary 
- Endometrium 
- Esophagus 
- Stomach 
- Pancreas 
- Bowel 
- Kidney 
- 9.Prostate 
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to weight excess (Hossain P, 2007). As shown in Figure 2, there is a parallel escalation of the 
two diseases. Both these metabolic disorders are characterized by defects of insulin action. 
 
Figure 2: Age adjusted prevalence of obesity and diagnosed diabetes among U.S. Adults 18 years or older 
The classical pathways from obesity to diabetes contemplated that the permanent elevation of 
free fatty acid (FFA) present in obesity, from one side leads to an accumulation of triglycerides 
in liver and in beta-cell, from the other side, leads to a predominant utilization of lipids by 
muscles with a concomitant inhibition of glucose transporter activity. These actions induce a 
diminution glucose uptake by muscles and decreased rates of glycogen synthesis by muscles 
themselves. Chronic hyperglycaemia, developed from these events, further impairs insulin 
sensitivity and leads to an increase of insulin secretion. The result is a pathological glycation of 
circulation proteins and formation of advanced glycation end products that worsen the 
pancreatic beta-cell insulin secretion and lead to beta cell apoptosis. 
These pathways supply a good explanation for the close association between weight gain and 
heightened risk of T2DM but they do not explain why not all individuals with obesity become 
diabetic, and certain individuals become diabetic after very minor weight gain. For this reason, 
in recent years an increasing number of works have studied common metabolic aspects and 
molecules in T2DM and obesity as sleep disturbances, androgens, vitamin D, gut hormones and 
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microbiota but the main common flaw between the two diseases probably, must be researched 
in the large individual variation that exist in the size and expandability of different adipose 
tissue depot and in the microvasculare dysfunction that occurs during AT growing.. Indeed, the 
growth and function of AT, depends on its vascularisation. If angiogenesis is inadequate, this 
may result in dysfunction of adipose tissue and it increases the risk of development T2DM. 
Evidences in rodents have shown that rapid adipose tissue growth induced by high-fat diet 
determinates hypoxia in response to expansion of adiposity; these results suggest that the 
response of adipose tissue may be insufficient to elicit sufficient compensatory angiogenesis. 
These data are concordant with some results which have shown how adipose tissue hypoxia is 
associated with fibrosis and inflammation, rather then a compensatory angiogenetic expansion. 
Moreover, alterations of adipokines pattern usually present in obese patients, is involved in the 
development of insulin-resistance up to diabetes type II. Initial condition of insulin-resistance 
is promoted by the reduction of adiponectin associated with increased levels of pro-
inflammatory cytokines, IL-6 and TNF- α. At the same time there is an increased release of 
free fatty acids (FFA) that contributes with a mechanism of lipotoxicity, actually FFAs act on 
pancreas inducing apoptosis of β-cells, as described above.  
Another interesting field of research is how adipose tissue behaves with overt T2DM disease. A 
vicious circle of progressive microvascular dysfunction due to AT inflammation and 
hyperglycaemia could be present. Hyperglycaemia, acting via oxidative stress, inflammation 
and advanced glycation end products, can worsening microvascular angiogenesis and function 
in AT but little is known about it. 
 
1.4 Obesity therapy 
In recent years, exciting advances have occurred in all 3 modalities used to treat obesity: 
lifestyle intervention, pharmacotherapy, and weight-loss procedures including bariatric surgery. 
Clinical trials have established the efficacy of lifestyle and behavioural interventions in obesity; 
moreover, there are now 5 weight-loss medications approved by the US Food and Drug 
Administration (FDA) for chronic management of obesity. Bariatric surgical practices have 
been developed and refined, together with improvements in pre- and postoperative care 
standards, resulting in better patient outcomes. 
Initial treatments are neither pharmacological nor surgical, actually they consist in 
modifications of life-style, based on a low-caloric intake dietary regime and increasing in 
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physical activity. Moreover cognitive behaviour therapy and/or psychological support are an 
integral part of obesity therapy (Europ G L). 
Indeed, the treatment of obesity needs a multidisciplinary skill that involved various specialists 
experienced in obesity management. For these reason on April 2011, at Padua University, was 
opened the Centre for the integrated treatment for obesity (CeSTIO) which comprise various 
operative unit and different specialists as physicians, surgeons, anaesthetists,  psychologists and 
psychiatrists, nutritionists and dieticians. 
1.4.1 Pharmacological Therapy 
As reported on European Guide Lines for Obesity Management in Adult (Rif. Biblio), 
pharmacological treatment should be considered as part of a comprehensive strategy of disease 
management. Pharmacotherapy can help patients to maintain compliance, ameliorate obesity-
related health risks and improve quality of life. It can also help to prevent the development of 
obesity co-morbidities (e.g. type 2 diabetes mellitus). The efficacy of pharmacotherapy should 
be evaluated after the first 3 months. If weight loss achieved is satisfactory (>5% weight loss in 
non-diabetic and >3% in diabetic patients), treatment should be continued otherwise should be 
interrupted. 
Pharmacological treatment is suggested for those patients who have BMI>30 kg/m2 and do not 
show any answer to life-style changes or BMI >27 kg/m2 in presence of complications. 
Mechanisms of action of weight loss medication focus mainly on appetite control. Except for 
orlistat, that acts on pancreatic lipases and so it reduces intestinal lipid absorption, medication 
for obesity acts on arcuate nucleus to stimulate the POMC neurons, which promote satiety. 
The 5 weight-loss medications approved by FDA are: 
- Locarserin 
- Phentermine/Topiramate 
- Bupropion/Naltrexone 
- Liraglutide 
- Orlistat 
The first third one are serotoninergic, as locarserin, no selective inhibitor of dopamine and 
norepinephrine transporters, as bupropione, or dopaminergic and noradrenergic, as 
phentermine.  The combination of phentermine and topiramate, which is a neurostabilizer and 
antiseizure medication, seems to be additive; however, it is unclear how topiramate enhances 
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appetite suppression. Naltrexone, an oppioide receptor antagonist, potentiates the effect of 
bupropione on activation of  POMC neurons. 
Liraglutide is a long acting GLP-1r agonist that acts in different way on the appetite control 
both directly on stomach where slows down gastric emptying and on POMC neuron too. GLP-
1r agonist is widely use in T2DM therapy so it is heavily indicated in obese patients affected by 
T2DM. 
Despite these 5 therapies approved by FDA, EMA (European Medicine Agency) approved just 
orlistat, bupropione/nalexone and liraglutide, while AIFA (Agenzia Italiana del Farmaco) 
approved only orlistat and liraglutide. Due to the unpleasant side effects of orlistat, steatorrhoea 
and fecal urgency, and to high cost of liraglutide, in Italy, pharmacological therapy for obesity 
is not so widespread. 
 
1.4.2 Bariatric Surgery 
Bariatric surgery has continued to increase in recent years, and over 340.000 procedures were 
performed in the world in 2011 (Buchwald H., 2013)  A recent systematic review concluded 
that bariatric surgery leads to a greater improvements in weight loss outcomes and weight 
associated co-morbidities compared with no surgical intervention, regardless of the type of 
procedure used (Colquitt JL., 2014).  
Surgery should be considered for patients aged 18–60 years with a BMI ≥ 40.0 kg/m 2 or with 
BMI between 35.0 and 39.9 kg/m 2 and co-morbidities, in whom surgically induced weight 
loss is expected to improve the disorder (such as type 2 diabetes and other metabolic disorders, 
cardiorespiratory disease, severe joint disease and obesity-related severe psychological 
problems). BMI criterion may be the current BMI or a documented previous BMI of this 
severity (Buchwald H., 2009).  
Recently, the scientific community debating to considered bariatric surgery in patients with a 
BMI lower than 35 Kg/m
2
 affected by T2DM, as there is evidence-based data supporting 
bariatric surgery benefits in regards to T2DM remission or improvement 
Nowadays it is possible to perform bariatric surgical interventions even before 18 years old and 
over 60 years old, when patients are accurately selected, nevertheless these categories are still a 
minority of the total amount of patients. 
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Exclusion criteria for Bariatric Surgery are: 
1. Absence of a period of identifiable medical management. 
2. Patient who is unable to participate in prolonged medical follow-up. 
3. Non-stabilized psychotic disorders, severe depression, personality and eating disorders, 
unless specifically advised by a psychiatrist experienced in obesity. 
4. Alcohol abuse and/or drug dependencies. 
5. Diseases threatening life in the short term. 
6. Patients who are unable to care for themselves and have no long-term family or social 
support that will warrant such care. 
 
Until a few years ago, bariatric  surgery procedures were divided into three groups: 
- Restrictive surgery which reduces the amount of ingested food; 
- Malabsorptive surgery which reduces the absorption of ingested food; 
- Mixed surgery a combination of the two mechanisms described before; 
 
In the first group were included gastric banding, sleeve gastrectomy and vertical gastroplastic, 
in the malasorbitive group were included duodenal-swith and Scopinaro bilio-pancreatic 
diversion and in the last group was included Roux en Y Gastric By Pass. Nowadays this 
classification is still valid but, the knowledges, emerged over time, regarding the effect of 
bariatric surgery on metabolic effects, have partially changed this classification. This is 
particularly true for SG that was considered initially a pure restrictive procedure, but it is now 
considered to act thorough several additional mechanisms as described below. 
All the types of bariatric surgery interventions might be performed with laparoscopic 
procedures, which must be considered as the first option: laparoscopic approach has many 
advantages compared to the laparotomic one, considering both post-surgical outcome and 
complications. Up to now there are not sufficient evidence-based data to suggest how to assign 
a patient to a specific bariatric/metabolic procedure with no evidence in favour of any particular 
procedure, even if several studies demonstrated that some of the bariatric procedures as SG and 
RYGB have early weight-independent metabolic effects on HbA1c, LDL cholesterol, blood 
pressure, prevention and reduced cardiovascular risks and lower surgical risks compared to 
other bariatric procedures (Lee WJ., 2011; Scopinaro N., 2011). For these reason,  in recent 
years, there was a progressive decreased of gastric banding, duodenal switch and bilio 
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pancreatic diversion and a progressive increased in gastric by pass and sleeve gastrectomy as 
shown in Figure 3 (data referring to Italy). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Bariatric surgery procedures from 2008 to 2014 in Italy 
1.4.2.1 Laparoscopic Adjustable Gastric Banding 
Laparoscopic Adjustable Gastric Banding consists of the placement of a silicon ring with a 
pneumathic chamber in the upper part of the stomach, in order to create a small gastric pouch in 
the subcardial area. The pneumathic chamber is connect to a silicon tube which ends up with a 
reservoir located in a subcutaneous position and it allows cutaneous regulation of the banding 
calibre. The goal is to induce early fullness and reduce the amount of ingested food. It is 
reversible and it does not lead to many complications. It determinates a decrease of body 
weight up to 40-50%, nevertheless about 60% of patients regain weight after a while and these 
is the reason why this bariatric procedure has shown a progressive decreased. 
 
1.4.2.2 Laparoscopic Sleeve Gastrectomy (LSG) 
Laparoscopic sleeve gastrectomy has been firstly proposed as the first step of a duodenal switch 
procedure, but subsequently evolved to an isolated procedure and, since 2008, it has markedly 
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increase in prevalence, raising from 5% to 27% of all bariatric procedures  (Buchwald H., 
2013) 
It consists of irreversible resection of 2/3 of the stomach and the cut is performed in order to 
make the stomach gain a tubular shape. The restrict residual volume is around 100-150 ml 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4: Sleeve Gastrectomy 
LSG was considered initially a pure restrictive procedure, but it is now considered to act 
thorough several additional mechanisms (Melissas J., 2007; Dimitriadis E., 2013). The 
mechanisms which lead to the loss of weight, are just partially due to the decrease of volume of 
the stomach, in fact gastric resection determinates alteration of hormonal asset. After LSG there 
is a decrement of ghrelin levels. Ghrelin is a hormone, mainly secreted by the fundus of the 
stomach, which have oroxogenic effects via stimulating neuropeptide Y from the hypothalamus 
and its levels are invertionally proportionate to BMI. Instead after LSG, there is no 
compensatory increase of ghrelin which should be associated to the weight loss, because of the 
gastric resection. Moreover, after LSG, increments of PYY and GLP-1 levels are usually 
observed. These hormones are secreted by the distal part of the intestine, they act on pancreatic 
cells increasing insulin secretion and they inhibit hypothalamic production of neuropeptide Y. 
In this way LSG is involved in inducing an improvement of diabetes type II up to resolution of 
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disease, independently from the weight loss.Weight loss is around 60% of body weight but 
long-term outcome are still unknown, so further investigations are still needed. 
 
1.4.2.3 Roux en Y Gastric Bypass (RYGB) 
Gastric bypass is the most commonly bariatric procedure performed worldwide. It consists of 
the creation of a small, (15–30 mL/1–2 tbsp) thumb-sized pouch from the upper stomach, 
accompanied by bypass of the remaining stomach (about 400 mL and variable). This restricts 
the volume of food which can be eaten. A segment of the small bowel (called the alimentary 
limb) is brought up to the proximal remains of the stomach. On the basis of the lengths of small 
intestine used, there are different degrees of food absorption. The most commonly gastric by 
pass is Roux en Y gastric by pass (Fugure 5) which contemplates the division of the small 
intestine approximately 45 cm below the lower stomach outlet and the  re-arranging into a Y-
configuration, enabling outflow of food from the small upper stomach pouch via a "Roux 
limb". The Roux limb is constructed using 80–150 cm of the small intestine, preserving the rest 
(and the majority) of it from absorbing nutrients. 
 
 
 
 
 
 
 
 
 
 
Figure 5: Roux en Y Gastric Bypass 
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The weight-loss is obtained thanks to the restrictive mechanism and partially to a mild 
malabsorptive mechanism, actually a decrease of ghrelin levels is usually observed. RYGB 
induces fast and sustained weight-loss, up to 60% of total body weight in the first year. It 
reduces global and cardiovascular mortality and obesity-related comorbidities. The mechanisms 
underlying these beneficial effects are multiple. Improvement of insulin-resistance or even to 
resolution of diabetes type II, occur within days after the surgical procedure is performed and 
before any substantial weight-loss, suggesting the hypothesis that the Glycaemic control is 
restored by mechanisms which are related to gut anatomical rearrangement and modification of 
flow of nutrients. Levels of GLP-1 increase rapidly after surgery is performed and not after 
dietary restriction despite similar weight loss, so GLP-1 might play a role in metabolic 
improvement achieved after RYGB. RYGB and LSG are considered similar for weight loss, 
improvement of co-morbidities and intra-operative and early postoperative safety. 
 
1.4.2.4 Hypoglycaemia after bariatric surgery  
In 2005, Service et al (Service GJ., 2005) reported, for the first time, cases of hypoglycaemic 
events occurring months to years after RYGB. Since then, an increasing number of publication 
demonstrated that postprandial hypoglycaemia (PPHG) is not so rare after RYGB and the 
frequency of asymptomatic hypoglycaemia may be over 30% (Goldfine AB., 2007). 
Comparable data for laparoscopic sleeve gastrectomy (LSG) are scantier. Recently, Natoudi et 
al. (Natoudi M., 2014) described the occurrence of severe hypoglycaemic events in 6/29 (37, 
5%) normoglycemic patients 12 months after LSG.  Moreover, Papamargaritis et al. found that 
33% of patients experienced hypoglycaemic events one year after LSG (Papamargaritis D., 
2012). 
Severe hypoglycaemia can lead to dangerous clinical consequences such as seizure, syncope, 
and motor vehicle accidents.  However, also mild-to-moderate hypoglycaemia (plasma glucose: 
2.3-3.9 mmol/L) can have a negative health impact in diabetic and no diabetic subjects.  Thus, 
in diabetic subjects mild-to-moderate hypoglycaemia can be associated with increased risk of 
cardiac arrhythmias. Furthermore, hypoglycaemia may reduce the amplitude of the blood-
oxygenation level dependent (BOLD) responses in primary auditory and visual cortex to simple 
auditory and visual stimuli (Driesen NR., 2007). 
Why some patients develop PPHG while others do not is unclear.  After bariatric surgery, 
alterations of gastrointestinal anatomy and of gastric innervation likely have a profound effect 
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on gastric emptying (Ukleja A., 2005).  Thus, meals are more rapidly transferred from the 
stomach to the small intestine, so that the distal intestine is exposed to higher loads of 
undigested carbohydrates, whereas absorption of glucose into the bloodstream is accelerated.  
The resulting hyperglycaemia stimulates a rapid and excessive secretion of insulin, which can 
in turn trigger late hypoglycaemia.  Other authors (Salehi M., 2011; Ukleja A., 2005) suggested 
the idea that excessive insulin secretion could be in part consequent upon increased incretin 
hormone release, but the role of these hormones in the development of hypoglycaemia remains 
controversial.  An increased secretion of GLP-1 and GIP has been observed after an oral 
glucose challenge in patients after gastric resection, esophagectomy, and RYGB (Romero L., 
2012), and these exaggerated responses have been suggested to induce ß-cell expansion via 
increased expression of islet transcription factors.  By contrast, in a recent paper it has been 
suggested that GLP1 analogs might provide a new treatment option in patients with late PPHG 
(Abrahamsson N., 2013).  Furthermore, it has been postulated that, after RYGB hypoglycaemic 
counterregulation may be dysfunctional, due to lack of inhibition of insulin secretion, 
subnormal response of the anti-insulin hormones, changes in neuronal/ sympathetic activity, 
and/or low glycogen stores (Salehi M., 2015). 
Therefore, recurrent hypoglycaemia of any degree can have clinical relevance and to identify 
predictive risk factors of this late complication of bariatric surgery becomes important. 
Moreover, very is known about PPHG after RYGB but little is known about PPHG after LSG. 
2. Adipose Tissue (AT) 
Adipose tissue was originally viewed as a connective tissue with a storage capacity, presently 
AT is considered an organized endocrine organ, both vascularised and innervated, with a clear 
anatomy and a high degree of plasticity responding to both corporeal and environmental 
changes. 
It was initially found surrounding the viscera in the peritoneal cavity, but later in evolution, 
major depots of adipose tissue were located in subcutaneous sites (Gesta S., 2007). 
Subcutaneous adipose tissue (SAT) is different in thickness and distribution according to sex: in 
women has a typical distribution involving the buttocks, the thighs, the abdomen under the bell, 
as a kind of "fat reserve" to protect the pregnancy; instead, in men, SAT follows a typical 
pattern of distribution which involves the face, the neck, the shoulders and, in particular, the 
abdomen over the bell with an increased risk of cardiovascular diseases (Mathieu P., 2009). 
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In the human body, AT is the only tissue that can expand, in adulthood, many times going from 
5% to 60% of total body weight. The increase of AT may be both hypertrophic and hyperplastic 
(especially but not only in the youth). The ability of adipose tissue to expand has clear 
evolutionary advantages, enabling survival in times of nutrient scarcity; however, concomitant 
with adipose tissue expansion are metabolic alterations that enhance risk of metabolic disease 
(Wajchenberg BL., 2000; Corvera S., 2014). 
In addition to a different distribution of AT, there are also different types of AT. In fact, AT, is 
distinguished in white (WAT), brown (BAT) and beige AT. The white adipocytes are spherical 
cells, large, uniloculate, with relatively low content of mitochondria and they contribute to 
forming deposits of subcutaneous and visceral adipose tissue. The BAT is formed by cells 
multi-vacuolated characterized by a high content of mitochondria with characteristic 
morphology (large size and ridges very developed) and it is well represented in new born baby 
while, in adult, small  residual island of BAT spreaded in WAT (Giordano A., 2014). At least, 
recently, a new cell type, the beige/brite adipocyte, has been described in the white depots of 
adipose organ, whose morphological, molecular and functional properties partly overlap brown 
cells (Wu, 2012). 
Taken as a whole, AT represents a complex organ with several functions. It represents the main 
deposit of triglycerides in human body and it is responsible, also, of triglycerides synthesis and 
release in form of glycerol plus fatty acids. In addition to storing excess triglycerides and 
releasing free fatty acids, AT in the form of white AT or brown/beige AT (BAT) is crucial for 
immune responses, thermo genesis, fertility and lactation (Harms M., 2013; Giordano A., 
2014). 
Then, as described above, the classical functions of adipose tissue are: 
- energetic reserve; 
- protection against mechanic trauma and mechanic support to different organs; 
- body shaping; 
- thermal isolation (white adipose tissue), increase body temperature and elimination of 
nutritional excess throughout thermal energy (brown adipose tissue); 
 
Furthermore, AT has metabolic and endocrine activities and the substances released may be 
divide into: 
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- Energetic compounds (free fatty acids, cheton bodies, glycerol); 
- Steroidal hormones (both androgens and estrogens); 
- Adipocytokines: Adiponectin, leptine,resistine, PAI-I, TNFα, IL-6 
 
2.1 Subcutaneous and Visceral Adipose Tissue 
In the 1950s, Vague was the first to suggest that the regulation of the endocrine and metabolic 
functions of abdominal AT were controlled, in part, by the anatomical distribution of fat with 
“android or male-type” obesity associated with T2DM and atherosclerosis (Vague J., 1956). 
From anatomically point of view, visceral AT (VAT) is centrally located and enclosed by the 
peritoneum, while the subcutaneous AT (SAT) is located directly below the skin. Both 
subcutaneous and visceral depots retain extraordinary growth potential throughout adult life 
(Utzschneider KM., 2004) but there is significant, heritable variation in the relative size of 
these depots (Fox CS, 2007). SAT and VAT differ in their cellular composition, their molecular 
properties, and their role in regulation of the whole body metabolism. 
There are few studies comparing human SAT and VAT, and they are increased in the recent 
years thanking to bariatric surgery. Due to the limitation of reproducible isolation methods and 
standardized cell size measurements, interand intra-individual data regarding depot-specific 
cellular characteristics are few. Adipocytes in general are smaller in VAT as opposed to the SAT 
of obese subjects even if, in some works, this trend is confirmed without a significant 
difference (O. Gealekman, 2011). Considering AT capillarization in different depot, works in 
literature are even less than those concerning adipocyte size. To our knowledge, only Corvera 
S. group has analyzed differences between SAT and VAT capillary density in 7 obese patients 
finding that subcutaneous adipose tissue capillary density is significantly higher compared with 
visceral adipose tissue (O. Gealekman, 2011). Due to the difficult to collect AT from lean 
subjects, especially visceral adipose tissue little is known about VAT and SAT of these patients. 
In literature, there are some more works compare obese's SAT with lean's SAT and they are all 
agree that adipocytes are smaller in lean/overweight as opposed obese (Goossens GH., 2011;  
O. Gealekman, 2011; Pasarica M. 2009). Regarding SAT capillary density between obese and 
lean, is confirm, in different works, that obese's SAT has a significantly lower capillary density 
compared to lean's SAT (Goossens GH., 2011; O. Gealekman, 2011; Pasarica M. 2009). None 
is known about capillary density of lean patients' VAT. From a functional point of view, 
classically, visceral adipose tissue is considered closely connected with the development of 
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insulin-resistance, dyslipidemia and increased cardiovascular risk (Cinti S., 1999). This concept 
is partially true; in the recent years several works have begun to demonstrate how even SAT 
plays an important role in the development of AT inflammation and so in the increased risk of 
insulin-resistance, dyslipidemia and cardiovascular disease. In fact, if on one side it has been 
demonstrated that an increased in abdominal AT is a risk factor for the development of 
metabolic disease, it has to be noted that the association reported between VAT and diseases in 
numerous epidemiological studies, used surrogate indexes of VAT, such as BMI, waist 
circumference, waist-to-hip ratio or waist-to-height ratio. In recent years, it has been shown that 
large subcutaneous fat cells are associated with insulin resistance and with a high risk of 
developing T2DM, and, studies following Roux-en-Y gastric bypass in women, have 
demonstrated that a reduction in SAT fat cell size correlates to improved insulin sensitivity 
(Andersson DP., 2014). Furthermore, in the first mentioned S. Corvera's work, have founded 
that the capacity of SAT to expand its capillary network decreases with morbid obesity and this 
decrease correlates with insulin resistance, suggesting that impairment of subcutaneous adipose 
tissue angiogenesis may contribute to metabolic disease pathogenesis (O. Gealekman, 2011). 
Besides, previous study of Snijder MB, has reported a different role for SAT dependent on its 
localization: SAT in the abdomen is directly associated with the metabolic syndrome in normal-
weight and obese men; while larger gluteo-femoral SAT is inversely associated with metabolic 
syndrome in both obese men and women (Snijder MB, 2005). 
Considering these indicated studies, it can be said that the classical distinction between SAT, as 
the safe AT, and the VAT, as the unhealthy AT it's no longer possible. Certainly, VAT has 
demonstrated to strongly influence the development of obesity-related disease but it is 
necessary, in the future, confirm these results using more specific methods of fat depot 
measurements and, it is necessary to consider also the excess of abdominal SAT as a negative 
event for health. Changing focus from visceral adipose tissue mass as a sole contributor to 
metabolic disease to functional heterogeneity in adipose tissue depots can help better 
understand relationship of adiposity and obesity-related disease. 
2.2 Adipose Tissue Endocrine Function 
The adipose tissue produces differents proteic substances, all together called adipocytokines, 
which are responsible for the interactions between the adipose tissue and other organs and 
systems, for instance the immunological one, the central nervous one and the endocrine one, in 
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order to regulate the human body metabolism. Some of these substances are not specific for the 
adipose tissue, for instance estrogens, PAI-1 and angiotensinogen. Some others are more 
specific like IL-1β, IL-6, TNF-α, MCP-1, resistine, and witch are involved in the development 
of insulin-resistance and chronic inflammatory state. Some factors specifically produced by 
adipose tissue, have a positive effect on metabolism, like adiponectin which increases insulin-
sensibility and has a protective role against the development of glucose intolerance and 
diabetes. In our study we measured, in particular, leptin, IL-6 and TNF-α. 
2.2.1 Leptin 
In 1949, a non-obese mouse colony being studied at the Jackson Laboratory produced a strain 
of obese offspring, suggesting that a mutation had occurred in a hormone regulating hunger and 
energy expenditure. In the following years, several studies, lead to discover a new obese-gene 
encoded a novel hormone that circulated in blood and that could suppress food intake: leptin. 
Leptin was the first fat cell-derived hormone (adipokine) to be discovered (Conde J., 2011). 
Leptin is a 167-aminoacids glycoprotein, codified by the gene ob located on chromosome 6. It 
is produced by white adipose tissue, in smaller amount by the muscular and neuronal tissue and 
by the gastric epithelium and mammarian epithelium. It is primarily involved in the regulation 
of food intake and energy expenditure. Although leptin reduces appetite as a circulating signal, 
obese individuals generally exhibit a higher circulating concentration of leptin than normal 
weight individuals due to their leptin-resistance. This leptin-resistance results from different 
mechanisms involving leptin receptor, leptin transport through blood brain barrier and post 
leptin receptor deficit. Normal sieric levels are between 5-21μg/L and they are increased in 
female subjects and in obeses, where leptin levels are directly proportional to the total amount 
of adipose tissue (linked to BMI) and the dimensions of adipocytes. 
Leptin receptors are located in several tissues (CNS, hepatocytes, myocytes, pancreatic cells, 
spleen cells, pulmonary tissue, ovarian tissue ) and also on immunological and endothelial 
cells; it can therefore talk about a pleiotropic role of this molecule (Ahima RS., 2000). One of 
the first leptin function to be discovered was the action on hypothalamic centres,  in particular 
in the hypothalamic arcuate nucleus, where leptin acts to decrease food intake and increase 
energy expenditure (Friedman JM., 1998) through the release of inhibitor neurotransmitter of 
appetite as α-MSH (α-melanocyte-stimulating hormone) and CART (cocaine and amphetamine-
regulated transcript respectively) and through the inhibition of neurotransmitter increased food 
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intake as NPY and with increasing thermo genesis (Vettor R., 2002). However it has been 
confirmed that leptin has multiple functions besides inducing the sensation of fullness, as 
reported in Figure 6. In particular, leptin may contribute to the development of classical risk 
factors of atherosclerosis such as arterial hypertension and diabetes mellitus, it may increase 
inflammation and it promotes platelets aggregation. It is known that leptin secretion by 
adipocytes is stimulated by insulin, so leptin plasmatic levels are closely correlated with insulin 
plasmatic levels. Recent works, have demonstrated that the effect of hypoxia on leptin secretion 
by human adipocytes is particularly marked and may indicate that a reduction in pO2 AT could 
be the primary mechanism for the rise in the production of leptin with obesity (Trayhurn P., 
2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Leptin's multiple functions. 
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2.2.2 IL-6 
Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-
inflammatory myokine. It is encoded by the IL6 gene. It has a pleyotropic functions as shown 
on Figure 7 and it is produced by several cellular types (monocytes, macrophages, endothelial 
cells, lynphocytes B and T, neutrophils, eosinophils, smooth muscle cells, skeletal muscle 
cells). The 20-30% of its production comes from adipocytes and this percentage considerably 
increased proportionally with increase of BMI and waist circumference (Park HS., 2005). 
 
Figure 7: Cells secreting IL-6 and cells undergoing its actions. 
IL-6 plays a crucial role in acute phase inflammatory response. It stimulates hepatic production 
of acute phase proteins like CRP and fibrinogen and its production is mainly induced by TNF-α 
and IL-1, two of the most important proinflammatory cytokines (Heinrich PC., 1999). It has 
been demonstrated that IL-6 is also involved in chronic inflammation, because its levels stay 
high in this phase as well (Gabay C., 2006). 
The increasing in inflammation may be the mechanism through IL-6 is involved in the 
pathogenetic process causing atherosclerotic disease, T2DM and every metabolic disease 
obesity-related. For T2DM, for example, IL-6, in addition to its immunoregulatory actions, has 
been supposed to affect glucose homeostasis and metabolism directly and indirectly by action 
on skeletal muscle cells, adipocytes, hepatocytes, pancreatic β-cells, and neuroendocrine cells. 
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Recent studies show that while there is evidence that circulating levels of IL-6 are elevated 
years before onset of type 2 diabetes, the role of IL-6 in precipitating T2DM is still an open 
question.  
In fact, there is no evidence for an independent role of IL-6 in impaired β-cell function and 
progressive β-cell apoptosis; no evidence in vivo demonstrating the role of IL-6 in causing 
impaired insulin-signalling in adipocytes and long-term IL-6 stimulation per se does not seem 
to cause insulin resistance in skeletal muscle. Taken together these results show that IL-6 may 
contribute to, but is probably neither necessary nor sufficient for development of type 2 
diabetes (Kristiansen OP., 2005). 
As leptin, IL-6 secretion by adipocytes is partially stimulated by insulin but some works by 
Trayhurn and also other authors, demonstrated in vitro, that the secretion of IL-6 by adipocytes 
may be partly a direct result of hypoxia within AT (Trayhurn P., 2008) 
 
2.2.3 TNF-α 
TNF-α is one of the most important proinflammatory cytokines, it is produced mainly from the 
macrophages, included macrophages which are located in the adipose tissue and by adipocytes 
themselves. TNF-α has several functions: it induces apoptosis and necrosis throughout inducing 
lyses of the cells, it promotes inflammation stimulating hepatic productions of proteins like 
PCR and it stimulates macrophages with an autocrine mechanism to produce different 
proinflammatory cytokines.  
TNF-α induces insulin-resistance, promotes the production of hormones (epinephrine, 
glucagon, cortisol) which increase gluconeogenesis and decrease glucose reabsorbition from 
skeletal muscle and adipose tissue, in addiction it decreases the production of adiponectin from 
adipocytes and inhibits the production and activation of the proteins which are involved in the 
insulin signalling pathway.  
In obese patients plasmatic levels of TNF-α are higher then in normal-weight subjects, at the 
same time TNF-α levels decrease together with the loss of weight. Plasmatic levels also 
correlate with insulinemia and insulin resistance. 
In vitro hypoxic adipocytes secrete TNF- α while Sun et al. has demonstrated that an enforced 
expression of VEGF in AT significantly down-regulated TNF-alfa expression. Taking together, 
these data shows once again that AT secretion of chemokines could be heavily affected by 
hypoxia. 
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2.3 Adipose Tissue Stem Cells (ASCs) 
Adipose tissue shows an extraordinary ability to change rapidly its dimensions, as otherwise 
just neoplastic tissues do, by hypertrophy (cell size enlargement) and hyperplasia (cell number 
increase), both in animals and in adult humans (Spalding KL., 2008). 
The concept of Mesenchymal Stem Cell was first introduced in the late sixties by isolation from 
bone marrow (BM-MSC) and just in 2000 from adipose tissue (ASC) (Zuk PA., 2001). In 2001 
the team of Zuk firstly described ASCs residing in adipose tissue depots and, actually, we fully 
recognize their real and potential value but their identity still remains elusive. 
Human ASCs are obtained from SVF, a heterogeneous cell population isolated from adipose 
tissue by the enzymatic digestion, centrifugation and removal of the differentiated adipocytes 
layer. Cultured cells show important differences compared to freshly isolated stromal cells, the 
latter one showing different percentages of CD34 positive (CD34+) cells depending on the 
source: adipose tissue specifically expresses higher levels of CD34 compared to bone marrow 
(Sidney LE., 2014). A recent comparative study by Pachon-Pena demonstrated how the surface 
antigens expressed by hASC and BM-MSC are for the major part similar in the 
immunophenotypic profile, differing fundamentally in the expression percentage of each of 
them (Pachon-Pena G., 2011). This observation sets these cellular entities more as a continuum 
rather than two distinct cellular precursors, their distinguishing features arising more from 
experimental settings (ex vivo or in vitro), number of culture cycles, cell proliferation grade, 
origin depot rather than from cellular intrinsic properties.  
ASCs were shown to express CD34 and their in vitro culture expansion leads to its rapid down-
regulation with a concomitant increase in four mesenchymal markers expression, CD13 (APN), 
CD73 (L-VAP-2), CD90 (Thy-1), CD105 (endoglin). The CD44 is another surface marker 
detectable on adipogenic progenitors, both in humans and in mice (Sousa BR., 2013). ASCs lie 
in close contact with other cell types among which pericytes and endothelial cells: pericytes 
belong to the mural cell compartment and carry out important functions especially in vascular 
development and maintenance (Gokcinar-Yagci B., 2015; Geevarghese A., 2014), endothelial 
cells differentiate from endothelial progenitor cells (EPCs), characterized by stem cell features, 
able to promote vascular regeneration by de novo capillary structures formation (Balaji S, 
2013). The close interactions between adipose progenitors, pericytes and endothelial cells and 
the open controversies about their exact origin still leave many questions open. Zimmerlin et al 
described three populations in the SVF: the luminal endothelial progenitor cells (CD45-
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:CD31+:CD34+), the adventitial pericytes (CD45-:CD31-:CD146+) and the supra-adventitial 
adipose stromal cells (CD45-:CD31-:CD146-:CD34+); a fourth subset, identified as 
CD146+:CD34+, showed an intermediate phenotype, being both highly proliferative and with 
an uniform mesenchymal marker profile (Zimmerlin, 2013) (Tallone T., 2011). 
Regarding ASCs and the different AT depot there are always more studies demonstrating how 
preadipocytes exhibit a site-specific gene pattern expression which is able to condition their 
behaviour also after isolation and several in vitro culture passages (Macotela Y., 2012), A four-
way study, in which subcutaneous and visceral adipose tissue were transplanted in SAT or VAT 
respectively, showed that just subcutaneous tissue transplantation into a subcutaneous or 
visceral site lead to beneficial effects, including body weight decrease with total adipose mass 
reduction and whole-body metabolic improvement. Placement of visceral tissue into the donor 
site did not determine relevant effects in terms of metabolic improvement.  
This observation implies the concept of a kind of “origin site cell memory” that can be kept 
despite the settings changes (Tran T.T, 2010). Again comparing human ASCs from abdominal 
SAT and VAT isolated and cultured in vitro, subcutaneous ASCs showed a much greater growth 
rate ability and adipogenic potential compared to visceral ones, by maintaining a high 
expression level of the polycomb gene BMI-1. Through electrophysiological properties 
analysis, the stem cell nature of both V-ASC and S-ASC was confirmed, suggesting that the 
differences between the two depots are probably determined at a stem cell level and 
“memorized” during later expansion (Baglioni S., 2012).  
A greater replicative potential of human subcutaneous preadipocytes compared to omental was 
already demonstrated: the number of subcutaneous precursors and the rate of clonal replication 
were higher with increased adipogenesis ability and lower apoptosis susceptibility (Tchkonia 
T., 2006). Despite this finding, some studies on human obese subcutaneous and visceral adipose 
tissue, demonstrated that also among V-ASCs there is a predominant hyperplasic grow instead 
of hypertrophic grow, this observation could be the response to the increased apoptosis rate 
detectable in this depot; visceral fat is much less malleable than the subcutaneous one, just a 
slight increase in cell size leading to huge changes in terms of metabolic implications. 
Moreover we could hypothesize that hyperplasia in VAT correlates with an abnormal and 
dysfunctional proliferation, nullifying the potential beneficial effects associated with this cell 
growth mechanism. Probably the past concept of hyperplasia as beneficial and hypertrophy as 
detrimental is applicable just in a pure and elementary model, in which “confounding factors” 
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such as location, innervations, vascularisation, epigenetic modulations and others do not need 
to be taken into consideration. 
Moreover, even though white and brown adipose tissue (WAT and BAT) seem to have a 
common mesodermal origin, recent studies shed light on the different adipogenic precursor. 
Indeed brown fat seems to share a common Myf-5 progenitor with skeletal muscle; white 
adipocytes originate from a non-Myf-5 precursor. The commitment through the adipogenic  
non-Myf-5 line or the myogenic Myf-5 one takes probably place at the mesenchymal stem cell 
stage (Wu J., 2013). Also regarding the beige AT, some studies suggest an independent origin of 
white and beige precursors in humans (Di Franco, Guasti et al. 2014). 
Another important notion concerning wit ASCs, is that the concept of stemness has been 
extensively reconsidered, being not just an intrinsic cell property, but rather a feature strictly 
conditioned by microenvironment.  
As for the best known hematopoietic niche, the adipose niche works as a specialized 
microenvironment that contributes to ASCs quiescence, maintaining their stemness, regulates 
their proliferation and differentiation. Extracellular matrix (ECM) forms the physiological and 
plastic scaffold, crucial for determining stem cell behaviour (quiescence versus proliferation 
and differentiation) and promoting proper contacts between ASCs and the other cellular niche 
components.  
Leptin, for example, secreted from mature adipocytes, regulates ECM composition, modulating 
the ASCs gene expression profile and therefore conditioning their behaviour in the adipose 
niche (McCulloch L.J., 2015); this observation provides evidence for a paracrine mechanism by 
which full differentiated cells regulate their own progenitors. The importance of 
microenvironment for the ASCs is well demonstrated in studies of obese AT where, as better 
described below, there is a hypoxia condition due to excessive AT expansion (Cao Y 2013; 
Corvera S., 2014) which further fires up the inflammatory response in a vicious loop. Many 
putative mechanisms seem to play a role in obese adipo-niche hypoxia establishment; although 
many questions still remain unanswered and controversial data are present in literature 
(Trayhurn P. 2013).  
In vitro studies using human ASCs demonstrated an enhanced proliferation in hypoxia (1% of 
pO2) conditions, suggesting that altered oxygen homeostasis could affect the quiescent-
activated ASCs balance (Kakudo N., 2015; Choi JR., 2014). Interestingly, hypoxia induces a 
pro-fibrotic program in ASCs, promoting the HIF1α up regulation on one side and the down 
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regulation of proteins involved in adipogenesis on the other (Rosenow A., 2013), thus 
perpetuating the pathological circle. Contrasting reports have demonstrated that human obesity 
does not show metabolic signs of AT hypoxia (Hodson L., 2013), even reporting data of an 
increased O2 tension (Goossens GH, 2011); however a normal O2 tension cut-off for adipose 
tissue has not been established yet.  
Beyond absolute oxygen tension, these data underlie the relevance of an altered oxygen flux in 
a pathological niche setting. Metabolic signals as well take probably part to the adipo-niche 
alterations. The often obesity-related diabetes development and thereby hyperglycaemia, 
implies advanced glycation products formation (AGEs) both in the extracellular and 
intracellular settings. AGEs are mostly represented by long life proteins, such as albumin, but 
ECM components could be a target of glycosilation too.  
In adipo-niche AGEs negatively affect ASCs pool by inducing cell apoptosis through AGE-
receptor (RAGE), as demonstrated in human ASCs when exposed in vitro to AGE-serum 
albumin (Wang Z., 2015). 
At least, an emerging field of research is represented by weight loss induced by the mean of 
bariatric surgery or long-term caloric restriction. Indeed, the analysis of ASCs properties before 
and after weight loss helps to better understand the role of cell and microenvironment 
contribution in metabolic disease development.  
S-ASCs from ex-obese individuals show a marked adipogenic commitment, probably as 
consequence of a precursors enrichment. This last observation has raised the hypothesis that 
hypertrophic adipocytes, after lipid mobilization in massive weight loss, could dedifferentiate 
again into preadipocytes (Baptista L., 2015), probably through a pericytes involvement in 
recruitment and generation from mature cells; indeed a fourfold increase in SAT supra-
adventitial cells was described in ex-obese patients compared to obese together with an 
increase in pericytes number in both groups compared to lean subjects (Silva K.R., 2015). 
 
2.4 Adipose Tissue Angiogenesis and Hypoxia 
One of the most remarkable features of adipose tissue is its capacity to expand in a 
nonneoplastic manner. While most of the growth of organs and tissues occurs during 
development, and their final size remains relatively constant through adulthood, adipose tissue 
is the unique tissue that can expand many folds also in adulthood.  
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The cellular and molecular mechanisms by which adipose tissue growth are coordinated with 
the expansion of its capillary network are unknown. These mechanisms may underlie the basis 
for adipose tissue dysfunction in metabolic disease. 
In each organ or tissue the angiogenesis comprise the proliferation of endothelial cells, their 
directed migration through the extracellular matrix, the establishment of intercellular junctions, 
the formation of a lumen, the organization of perivascular supporting cells, the anastomosis 
with existing vessels, and the establishment of circulation.  
The main event of angiogenesis is the stimulation of endothelial cells proliferation by Vascular 
Endothelial Grow Factor (VEGF). VEGF-A, acting through its receptor, known with the name 
of VEGF Receptor 2 or KDR, is the most powerful signal for migration and mitogenesis of 
endothelial cells. In response to the increase of the concentration of VEGF-A, the endothelial 
cells are able to divide and to acquire a specific phenotype characterized by the formation of 
branches and numerous filipodi that extend toward the direction where the endothelial cells 
must migrate.  
But, even if the basic steps of angiogenesis are well known, the microenvironment deeply 
influence the angiogenesis and little is known about the mechanism operating in adipose tissue. 
As reported in S. Corvera review (Corvera S., 2014), there are two possible models for the 
stimulation of angiogenesis during adipose tissue growth. The first one contemplates that an 
increasing calorie consumption results in adipocyte hypertrophy and hyperplasia, which can 
generate areas of tissue hypoxia.  
Hypoxia, and/or other factors released from the tissue are able to stimulate angiogenesis. 
Angiogenesis could result in mitigation of hypoxia with an appropriate tissue architecture and 
function. The second one contemplates that the increasing calorie consumption results in 
systemic changes in trophic factors such as insulin, which directly stimulate angiogenesis 
within adipose tissue. Increased angiogenesis facilitates lipid storage in adipocytes and 
adipocytes' hyperplasia.  
The simultaneous expansion of adipocytes and vasculature could prevent development of 
hypoxia and metabolic stress (Figure 8) Which of the two mechanisms is involved, or if they 
are both involved, in AT angiogenesis is not yet known but several studies both on cellular 
cultures, animal models and human adipose tissue, reported that an impaired angiogenesis is 
involved in AT dysfunction and obesity-related diseases. 
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Figure 8: two possible mechanisms of adipose tissue angiogenesis (adapted from S. Corvera review) 
 
Pasarica, Goosens and Gealekman's works have demonstrated a significantly reduction in both 
capillary density and VEGF m-RNA  in obese AT compared to lean AT (Pasarica M., 2009, 
Goossens GH., 2011, Gealkmann O., 2001). 
The impaired AT angiogenesis could be the primum movens of AT dysfunction with particular 
regard to insulin-resistance and diabetes. Indeed, microvasculature plays a central role in 
glucose homeostasis: an impaired capillary recruitment and capillary rarefaction may reduce 
glucose uptake and contribute to insulin resistance (Levy BI, 2008). 
Even if in human AT, contrasting results regarding AT pO2 are reported, several studies showed 
that AT is hypoxic but this hypoxia is inadequate to sustain the neoagiogenetic response 
however triggers AT fibrosis contributing to a worse metabolic profile (Sung HK, 2013). 
Indeed, structural and functional abnormalities, such as lower capillary density (Pasarica M, 
2009; Gealekman O, 2011), increased adipocyte-capillary distance due to adipocyte 
hypertrophy (Halberg N, 2009) and increased cell O2-consumption (Lee YS, 2014), have been 
41 
postulated as mechanisms leading to AT hypoxia.  Furthermore low oxygen tension induces 
hypoxia-inducible factor 1 alpha (HIF1α) pathway that, in obese AT, was found to be higher 
than in lean AT. HIF1α is a transcriptional regulator of more than 100 different genes. Encoding 
for proteins involved in a multiplicity of cellular process, including glucose utilization, 
inflammation, ECM metabolism and apoptosis. 
In AT, HIF1α is unable to induce an angiogenic program but, the presence of HIF1α induces an 
alternative transcriptional program, mainly entailing enhanced synthesis of ECM components, 
leading eventually to the development of fibrosis. As it has been well explained by Sun in its 
review published on Cell Metabolism (Figure 9), hypoxia and then, HIF1α, unregulated  a 
whole set of ‘‘fibrotic response’’ gene. This regulation results in the abnormal development of 
ECM, leading to local fibrosis, which triggers necrosis of adipocytes. The dead adipocytes then 
attract classically activated proinflammatory M1 macrophages, which ultimately lead to 
inflammation and metabolic dysfunction. Moreover HIF1a may also directly induce 
proinflammatory factors, such as IL6 and MIF, which in turn causes M1 macrophage 
infiltration.  
 
Figure 9: Proposed Models for the Sequential Steps Leading to Adipose Tissue Fibrosis and Metabolic 
Dysfunction 
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The preadipocytes, macrophages, and interactions between these cell types ultimately produce 
fibrotic components, which eventually cause pathological expansion of fat pads (Sun K. 2013). 
These two mechanisms, able to explain the linking between obese fat expansion, hypoxia and 
metabolic disease, are well demonstrated in cultured cells and in mice-models but not 
thoroughly in human. 
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3.  AIMS  
3.1 AIMS (1) 
Type 2 diabetis mellitus (T2DM) and obesity are global health care problems that are closely 
linked together. The precise mechanisms linking the two conditions remain unclear. Indeed, 
while the close relationship between T2DM and weight gain is well established, not all obese 
subjects are diabetic and this paradox is still unexplained.  
We hypothesized that adipose tissue (AT) and its microvascularization could play a pivotal role 
in this paradox. 
Therefore, our project primary aims to characterize AT, through ex vivo/in vitro studies, in 
terms of adipocytes size, capillary density, adipose tissue stem cells (ASCs), endotelial 
precursor cells (EPs) of AT and adipogenic potential, in obese subjects compared to lean 
subjects; secondary, aims to find the possible differences between the two distinct adipose 
tissue depot, subcutaneus and visceral adipose tissue (SAT and VAT) both in obese and in lean 
subjects; finally, aims to discover if there are any differences, in the same terms describe 
above, in SAT and VAT of obese patients with different glycaemic profile. Moreover, in a small 
number of patients, we aim to characterize SAT after a significant weight loss in terms of ASCs 
and EPs compared to obese patients SAT and lean patients SAT. 
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3.2 AIMS (2) 
 
Currently, bariatric surgery is the most effective therapy for weight loss and and weight 
associated co-morbidities.  
Among bariatric surgery procedures, laparoscopic sleeve gastrectomy (LSG) is markedly 
increased in prevalence, raising from 5% to 27% of all bariatric procedures, in the recent years. 
The beneficial effects of this bariatric procedure are well known, while are lesser known side 
effects. In particular, postprandial hypoglycaemia, is a well described side effect after RYGB 
but few data are available for LSG. 
Primary aims of this study are: verify the prevalence of provocative hypoglycaemia after LSG 
in a large number of non diabetic obese patients and  identify any predictors of these events 
before surgery. 
Secondary aims are: evaluate the effects of LSG, after one year, in the same population and if 
there are any differences in anthropometric and metabolic parameters after LSG between 
patients with and without hypoglycaemic events . 
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4. MATERIALS and METHODS 
 
4.1 MATERIALS and METHODS (1) 
 
4.1.1 Ethic Statements 
The Padua Ethical Committee for Clinical Research approved the study involving patients and 
each subject gave informed written consent for adipose tissue biopsy (2892P). 
 
4.1.2 Human Subjects 
We collected subcutaneous (SAT) and/or visceral (VAT) adipose tissue (AT) from 249 patients 
divided in 5 different groups: 18 lean normal weight and normoglycemic subjects (18.5 < BMI 
< 24,9 kg/m2) as control group, 68 normoglycemic obese subjects (ob N), 65 pre-diabetic 
obese subjects (ob pre-T2DM), 57 diabetic obese subjects (ob T2DM) and 41obese patients 
underwent to a relevant weight loss (ob WL), corresponding to at least 10% of body weight.  
All obese patients were enrolled in our (Ce.S.I.T.O.) from January 2014 to June 2016. Every 
obese subject received a baseline clinical evaluation which included collection of clinical 
history, physical examination, anthropometry, blood pressure measurement and blood 
samplings (complete blood count, liver, kidney and thyroid function markers, TNF-α, IL-6, hs-
CRP, leptin and lipid profile). Moreover a 3-hour 75 g OGTT for blood glucose (BG), insulin 
plasma levels, c-peptide was performed. In diabetic patients fasted blood glucose, insulin (for 
non-insulin treated subjects) and HbA1c was determined. Insulin sensitivity was estimated by 
HOMA IR. All biochemical analysis were performed as described below (Materials and 
Methods 2, Patients). On the basis of the glycaemic profile according to ADA criteria (ADA, 
2016) obese patients were classified in 3 groups: ob N, ob pre-T2DM and ob T2DM. AT 
samples from obese patients were collected during bariatric surgery by the same chirurgical 
team (Bernate P., 2006). 
Lean subjects were enrolled, as control group, in the General Surgery Unit or in Clinical 
Surgery I of Padua Hospital, and SAT and VAT samples were harvested during abdominal 
surgery as laparoscopic cholecystectomy or fundoplication surgery, or SAT alone during plastic 
surgery for minor abdominal wall defects. For each lean subject we collected clinical history, 
anthropometry, blood pressure measurement and blood samplings (complete blood count, liver 
and kidney function markers and fasting glucose). The exclusion criteria for the selection of 
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lean subjects were: a history of malignancy (the patients included in the study must be free of 
the disease for at least 5 years), chronic inflammatory diseases, infectious diseases in progress 
and T2DM. 
After sampling, tissues were partly immediately frozen in liquid nitrogen and stored at -80°C 
before further assays and partly formalin fixed for immunohistochemical analysis (HIC). 
Moreover, when sufficient tissue was available, it was used to isolate stromal vascular fraction 
(SVF) cells to set up adipocytes primary cultures and/or to flow cytometry analysis.  
 
4.1.3 Histological and Immunohistochemical Analysis  
SAT and VAT samples of 5 ob N, 5 ob pre-T2DM, 5 ob T2DM and 6 lean subjects were 
formalin fixed, paraffin embedded, sectioned 5 μm thick and floated onto charged slides.  
4.1.3.1 Adipose Tissue Capillarization 
Paraffin-embedded AT sections were stained with a specific endothelial marker (Monoclonal 
Mouse Anti-Human CD31, Clone JC70A, Dako) and observed under Leica DM LB2 
microscope. Digital images were captured with the use of a Leica DFC450C digital camera, in 
at least 10 random fields at 20X magnification (at least 200 random adipocytes per tissue 
biopsy were counted). The number of capillaries for every adipocyte were manually counted 
and the capillary density was expressed as number of capillaries per mm
2
 and as average 
adipocyte area (μm2) sprayed by one capillary (adipocyte area/capillary). 
4.1.3.2 Adipocyte Size  
Adipocyte area was measured on the same digital images captured with the use of a Leica 
DFC450C digital camera, in the same samples and fields used for the analysis of AT 
capillarization. Area of each adipocyte was manually counted using LAS software (Leica 
Microsystems). Approximately 200 adipocytes per sample were measured. 
 
4.1.4 Human Adipocytes Primary Cultures and Flow Cytometry Analysis 
4.1.4.1 Stromal Vascular Fraction Extraction  
SAT and VAT were minced, digested in collagenase type II solution (1 mg/ml) (Sigma-Aldrich, 
St. Louis, MO, USA) on a shaking water bath at 37°C for 1 h, centrifuged 10 minutes at 350 
xg, and red blood cells were lysed using lysis buffer (NH4Cl 1.545 M, KHCO3 100 mM, EDTA 
1.27 mM) as previously described (Sanna M., 2009).  
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4.1.4.2 Flow Cytometry Analysis 
SAT samples of 24 ob N, 18 ob pre-T2DM, 23 ob T2DM, 5 lean subjects and 17 ob WL and 
VAT samples of 26 ob N, 25 ob pre-T2DM, 30 ob T2DM and of 10 lean subjects were used to 
isolate SVF and to perform multiparameter flow cytometry.  
10
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SVF cells freshly isolated from SAT and VAT of the indicated patients were washed whit 
cold FACS buffer (2% BSA in PBS 1X), collected by centrifugation at 350 xg for 8 minutes, 
and simultaneously incubated in the dark for 10 minutes at room temperature with the 
following monoclonal primary antibodies, as indicated in Figure 10: CD31-FITC and -PE, 
CD45-FITC, CD34-PerCP-Cy5.5, CD44-PE, CD73-APC, CD90-PE, CD105-APC, CD271-
APC, CD146-PE (BD Biosciences) specific for membrane markers used to quantify and 
characterize Adipose Stem Cells (ASCs), endothelial precursor and mature cells and 
pericytes/mural cells (Zimmerlin L, 2010; Tallone T, 2011).  
 
Figure 10 . Schematic protocol for antibody staining for multiparametric FACS analysis. 
After washing with FACS buffer (2% BSA in PBS 1X), cells were collected by centrifugation 
at 350 xg and resuspended in 200 µL of FACS buffer. As negative control, the fluorescence 
signals were detected using isotype-matched PE-IgG1, FITC-IgG1, APC-IgG1 and PerCp-
Cy5.5-IgG1 monoclonal antibodies. Cells were analyzed by FACS Canto Flow Cytometer (BD 
Biosciences, San Jose, CA, USA). 
This method allows to determine ex vivo the percentage of cells in the SVF that co-express the 
different markers in the absence of expression alterations due to culture conditions. 
 
4.1.4.3 Human Adipocyte Primary Cultures  
SAT samples of 18 ob N, 15 ob pre-T2DM, 14 ob T2DM and VAT samples of 20 ob N, 25 ob 
pre-T2DM, 23 ob T2DM were used to isolate SVF to perform human adipocytes primary 
culture in order to evaluate the in vitro adipogenic potential.  
1x10
5
 SVF cells/well were seeded in duplicate in 96-well plate (BD Biosciences) in human-
standard medium (h-SdM): 10% FBS DMEM F12 supplemented with 150 U/ml streptomycin, 
Tube FITC PE PerCP-Cy5.5 APC
1
2 ms IgG1 isotypic control  ms IgG1 isotypic control  ms IgG1 isotypic control  ms IgG1 isotypic control  
3 CD45   CD31     CD34     
4 CD31 CD13    CD34 CD29     
5 CD31 CD90  CD34   CD73 
6 CD31   CD146    CD34    CD271
FVSc
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200 U/ml penicillin, 2 mM glutamine, 1 mM HEPES (Thermo Fisher Scientific). At cell 
confluence (1-2 days after seeding), medium was replaced with human-adipogenic medium (h-
AdM): DMEM F12 (with 150 U/ml streptomycin, 200 U/ml penicillin, 2 mM glutamine, 1 mM 
HEPES) containing 66 nM insulin, 100 nM dexamethasone, 1 nM T3, 10 μg/ml transferrin, 33 
μM biotin, 17 μM pantothenate, 0.25 mM IBMX, 10 μM rosiglitazone. IBMX and 
rosiglitazone were removed after 3 days of culture, cells were further differentiated in h-AdM 
until day 9 when the percentage of mature adipocytes per well was estimated by optical 
microscopy using a Leica DM IL LED Microscope equipped with camera. 
 
4.1.5 RNA Extraction and RT-Real time PCR 
Total RNA from matched SAT and VAT samples of 20 ob N, 22 ob pre-T2DM, 22 ob T2DM, 
13 ob WL and of 6 lean subjects was extracted using RNeasy Mini Kits (QIAGEN, GmbH, 
Hilden, Germany) according to supplier instructions. RNA content was quantified using 
NanoDrop technology (Fisher Scientific SAS, Illkirch Cedex, France) and quality-checked 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, PaloAlto, USA).  
RNA samples were then treated with DNase Treatment & Removal Reagents (Ambion, Inc, 
Austin, TX, USA) and reverse-transcribed for 1 h at 37° C with 150 ng random primers, 0.5 
mM dNTPs, 20 units of RNAsin Ribonuclease Inhibitor and 200 units of M-MLV RT 
(Promega, Madison, WI, USA). Real Time PCR was carried out with SYBR Select MasterMix 
(Thermo Fisher) on an Applied Biosystems 7900HT Fast Real-Time PCR System. Duplicate 
samples (5 ng of cDNA) were normalized by the indicate reference gene and reported as 
arbitrary units ratio.  
Primers sequences and reaction conditions were reported in Table IV. 
Table IV. Primes sequences and real time PCR reaction conditions used. 
GENE FORWARD (5'-3') REVERSE (5'-3') ANNEALING (°C) PRIMER (F/R nM) AMPLICON (bp) 
RPLP0 GCAGCATCTACAACCCTGAA CAGACAGACACTGGGAACAT 60 300/300 95 
PPARg2 ACCCAGAAAGCGATTCCTTCA AGTGGTCTTCCATTACGGAGAGATC 60 900/900 87 
LEPTIN GTGCGGATTCTTGTGGCTTT GGAATGAAGTCCAAACCGGTG 63 100/100 174 
VEGFA TCACCATGCAGATTATGCGGA TGTTGTGCTGTAGGAAGCTCA 58 300/300 75 
VEGFR1 
(FLT1) 
CGCCGGAAGTTGTATGGTTAAAA AGCCACGAGTCAAATAGCGAG 58 300/300 72 
VEGFR2 (KDR) CCGTTAAGCGGGCCAATGGA TTCAGCCGGTCTCTGGGGAA 60 300/300 142 
HIF1A TTACCATGCCCCAGATTCAG GGTTCTTTGCTTCTGTGTCTTC 58 300/300 180 
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4.1.6 Statistical Analysis 
In dependence of their distribution according to Shapiro Wilk normality test data, are presented 
as mean ± SD or median, minimum and maximum values. Statistical significance was 
determined using test t for normal distributed variables and Mann-Whitney non parametric test 
for skewed data. Differences were considered significant with p < 0.05.Correlation analysis 
was performed using both linear correlation and Spearman’s rank correlation coefficient 
calculation by STATISTICs Software (StatSoft 7.1)  
 
4.2 MATERIALS and METHODS (2) 
4.2.1 Ethic Statements 
The Padua Ethical Committee for Clinical Research approved the study involving patients and 
each subject gave informed written consent for adipose tissue biops y (2892P). 
 
4.2.2 Patients 
We analysed a total of 197 consecutive non-diabetic morbidly obese patients (140 women and 
57 men, BMI 47.4 ± 7.3 Kg/m
2
, mean ± SD) who underwent to laparoscopic sleeve 
gastrectomy (LSG) in our Center for the Study and the Integrated Treatment of Obesity 
(Ce.S.I.T.O.).  
All patients were studied 12 months before and after LSG. LSG was performed by the same 
surgical team with the same procedures (Bernate P., 2006) in patients with a BMI greater than 
35 Kg/m
2
 in the presence of co-morbidities or with a BMI greater than 40 Kg/m
2
, according to 
the NIH consensus criteria for bariatric surgery (NIH, 1991).  
Pre-operative evaluations included anthropometrics parameters, medical history, clinical 
examination, dietary counselling, complete blood count, complete metabolic panel including a 
3- hour OGTT for blood glucose (BG), insulin plasma levels and c-peptide, interleukin-6 (IL-
6), tumor necrosis factor alpha (TNF-α) and highly sensitive C-reactive protein (hs-CRP). 
Abdominal ultrasound, upper gastrointestinal endoscopy and upper gastro-intestinal barium x-
ray were also performed before surgery.  
Patients with a history of T2DM according to ADA criteria (ADA 2016) were excluded from 
the present analysis. One year after surgery all patients were evaluated with the same blood 
analysis, anthropometrics parameters and clinical examination. All blood tests were done after 
8 hours fasting. Plasma glucose, insulin and C peptide were collected at basal time and after 
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30, 90, 120, 150, 180 minutes after glucose load (180 ml of syrup with 82.5 g glucose 
monohydrate equal to 75 g of glucose). Hypoglycaemia was defined as the detection of a BG 
level ≤ 2.7 mmol/l at any time during OGTT.  
Blood samples were used for the biochemical determinations, performed with standard 
diagnostic kit: glucose (Glucose HK Gen.3 Cobas C System, Roche Diagnostic, USA), insulin, 
IL6, TNFα (IMMULITE 2000 Insulin, IMMULITE 1000 Immunoassay System, IL-6 and 
TNFα, Siemens Healthcare GmbH, Germany), hsCRP (Cardiophase Flex reagent Cartridge, 
Dimension Vista, Siemens) and Leptin (RIA – CT, Mediagnost, Germany) was standardized 
according to WHO First International Reference Standard.  
Glucose and insulin areas under the curve (AUC) were calculated. The homeostasis model 
assessment (HOMA) was calculated and used as insulin resistance index (Bonora A, 2000). 
Ideal body weight was calculated as weight which give patients an hypothetical BMI of 25 
Kg/m
2
and it was used to calculate the percentage of the excess BMI (%EBMI) and the 
percentage of excess BMI loss (%ELBMI).  
 
4.2.3 Statistical Analysis 
Data are expressed as mean ± standard deviation, except as otherwise indicated. The 
frequencies of hypoglycaemic events and severe hypoglycaemic events are expressed in 
percentage. Differences in the frequencies of hypoglycaemic events observed before and after 
LSG were tested by Chi-square test.  
Numerical data at baseline and after 12 months were compared with the use of a paired 
Student’s t- test. Patients with and without hypoglycaemic events were compared with unpaired 
Student’s t- test. Predictors of hypoglycaemic events were investigated with the use of a 
multiple logistic regression analysis model.  
In this model, the occurrence of hypoglycaemia (BG <3.3 mmol/l) at any time during the test 
was used as the dependent variable. Sex (male =0; female =1), age, BMI before surgery, and 
the baseline variables found to have a significant difference between patients with and without 
hypoglycaemic events after surgery were entered as independent variables in the multiple 
regression analysis. In all statistical analysis, a p-value <0.05 was considered to be significant. 
Statistical analysis was performed by using the SSPS statistical package, version 21.0 (SSPS, 
Chicago, IL). 
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5. RESULTS 
 
5.1 RESULTS (1) 
5.1.1 Patients 
5.1.1.1 Clinical Evaluation of Obese Patients 
We analyzed SAT and/or VAT samples from 190 consecutive obese patients underwent to 
bariatric surgery, whose main demographic, anthropometrics and metabolic parameters are 
reported in Table V. On the basis of their glycaemic profile, patients were divided in three 
different groups, 68 patients were normoglycemic (ob N), 65 were pre-diabetics (ob pre-
T2DM) and 57 were diabetics (ob T2DM). The three groups did not statistically differed in 
terms of BMI (46 ± 8; 47 ± 7; 48 ± 8 kg/m
2
) and Leptin plasma levels (40 ± 15; 40 ± 16; 35 ± 
16 μg/l), while ob T2DM showed a waist circumference (WC) larger than ob N and ob pre-
T2DM (137 ± 16; 127 ± 13; 128 ± 20 cm; p < 0,001 and p < 0,05 respectively). Moreover, ob 
T2DM were older than ob N and ob pre-T2DM and also ob pre-T2DM were older than ob N 
(52 ± 9; 47 ± 11; 40 ± 10 yrs; ob T2DM vs ob N p < 0,00001; ob pre- T2DM vs ob N p < 
0,001; ob pre-T2DM vs ob T2DM p < 0,01).  
The three co-morbidities considered, blood hypertension, dyslipidemia and Obstruction Sleep 
Apnea Syndrome (OSAS), have seen a progressive increase in terms of percentage of patients, 
from ob N to ob T2DM groups. Indeed, hypertension was present in the 37% of ob N, in the 
54% of ob pre-T2DM and in the 91% of ob T2DM; half of ob N and ob pre-T2DM patients 
were affected by dyslipidemia which was present in the 77% of ob T2DM. Finally, OSAS was 
present in only 5% of patients in ob N group, increasing to 28% in the ob pre-T2DM and 42% 
in the ob T2DM groups. 
As expected by the selection criteria used, the 3 groups differed significantly in fasting blood 
glucose level, mmol/l (5 ± 0,4; 5,9 ± 0,5; 9,4 ± 4; p < 0,000001), and ob N compared to ob pre-
T2DM showed higher levels of basal insulin mU/l (16,5 ± 9,7; 25,8±19,4; p < 0,001) and lower 
levels of HOMA -IR (3,7 ± 2,3; 6,8 ± 5,7: p < 0,0001). We did not evaluate insulin levels and 
HOMA -IR in ob T2DM patients because 20 out of 57 patients were on therapy with insulin. 
The others ob T2DM were treated with metformin (46/57) alone or associated to insulin or 
other hypoglycemic drug treatment as sulfonylureas (3/57), thiazolidinedione (1/57), GLP-1r 
agonist (4/57); 4 ob T2DM patients were not on therapy at the time of blood tests and 3 were 
started on metformin therapy, while just 1 was following diet therapy till the surgery. Among 
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ob T2DM 24 out of 57 patients had a history of T2DM longer of 5 years, 13 out of 57 had a 
history of T2DM lesser than 5 years, 20 out of 57 had a history of T2DM lesser than 1 year. 
HbA1c levels in ob T2DM was 66 ± 21 mmol/mol (range 38-122 mmol/mol). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table V. Demographic, anthropometrics and metabolic parameters of obese patients analyzed by AT 
biopsies collection. BMI: Body Mass Index. Hyp: blood hypertension. DLP: dyslipidemia. OSAS: obstructive 
sleep apnea syndrome. BMI: Body Mass Index. HOMA-IR: Homeostasis Model Assessment. T-CHL: total 
cholesterol. HDL: High Density Lipoproteins. LDL: Low Density Lipoproteins. TGL: triglycerides. hs-PCR: High 
sensitive C-Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor Necrosis Factor-alpha. Results were reported as 
means ± DS; statistical analysis was performed by paired Student’s t-test. 
 
In regard to systemic inflammation markers statistical differences were obtained between ob N 
compared to ob T2DM in term of TNF-  7,7 ± 2,3; 9,9 ± 6,7 ng/l; p < 0,05) and between ob N 
compared to ob T2DM (3,4 ± 2,4; 4,4 ± 2,4 ng/l; p < 0,05) and ob pre-T2DM compared to ob 
T2DM (3,3 ± 1,3; 4,4 ± 2,4 ng/l; p < 0,001) in term of IL-6. Blood level of hsPCR was not 
significantly different among the 3 groups of patients (7,8 ± 15,9; 7,6 ± 4,2; 7,6 ± 3,2 mg/l).  
Finally, concerning the lipid profile, significant differences were observed only in diabetic 
patients (ob T2DM) which displayed lower levels of HDL-cholesterol (43 ± 11 mg/dl; 48 ± 12; 
p < 0,05) and higher level of triglycerides (166 ± 89; 115 ± 57 mg/dl; p < 0,05) when compared 
with normoglycemic obese subjects (ob N). We have to notice that there was a progressive 
worsening in the lipid profile from ob N, ob preT2DM to ob T2DM groups taking into account 
 ob N 
 
 
(n = 68) 
ob pre-
T2DM 
 
(n = 65) 
ob T2DM 
 
 
(n = 57) 
p 
 
ob N 
 vs   
ob pre-
T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-T2DM 
vs  
ob T2DM 
 
Sex (F/M) 55/13 50/15 32/25    
Age (years) 40 ±10 47 ± 11 52 ± 9 <0,001 <0,00001 <0,01 
HYP (n; %) 25 (37%) 35 (54%) 52 (91%)    
DLP (n; %) 34 (50%)  34 (52%) 44 (77%)    
OSAS (n; %) 5 (7%) 18 (28%) 24 (42%)    
BMI (Kg/m2) 46 ± 8 47 ± 7 48 ± 8 ns ns ns 
Waist(cm) 127 ± 13  128 ± 20 137 ± 16 ns <0,001 <0,05 
Blood Glucose (mmol/l) 5 ± 0,4 5,9 ± 0,5 9,4 ± 4 <0,0000 <0,0000 <0,0000 
Insulin (mU/l) 16,5 ± 9,7 25,8±19,4 - <0,001 - - 
HOMA-IR 3,7 ± 2,3 6,8 ± 5,7 - <0,0001 - - 
HbA1c (mmol/mol) - - 66 ± 21 - - - 
T-CHL (mg/dl) 186 ± 29 193 ± 37 184 ± 43 ns ns ns 
HDL (mg/dl) 48 ± 12 46 ± 12 43 ± 11 ns <0,05 ns 
LDL (mg/dl) 116 ± 25 121 ± 36 110 ± 37 ns ns ns 
TGL (mg/dl) 115 ± 57 139 ± 77 166 ± 89 ns <0,05 ns 
hsPCR (mg/l) 7,8 ± 15,9 7,6 ± 4,2 7,6 ± 3,2 ns ns ns 
TNF-α (ng/l) 7,7 ± 2,3 8,7 ± 7,4 9,9 ± 6,7 ns <0,05 ns 
IL-6 (ng/l) 3,4 ± 2,4 3,3 ± 1,3 4,4 ± 2,4 ns <0,05 <0,01 
Leptin (ug/l) 40 ± 15 40 ± 16 35 ± 16 ns ns ns 
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that ob N patients were not treated and, on the contrary, 3 out of 65 ob pre-T2DM patients and 
20 out of 57 ob T2DM patients underwent to statin therapy. 
5.1.1.2 Lean Subjects and Obese Patients After Weight Loss. 
We collected SAT and/or VAT samples from 18 non-diabetic lean subjects and 41 obese 
patients after weight loss (ob WL), whose main demographic, anthropometrics and metabolic 
parameters are reported in Table VI.  
Nine SAT and/or VAT biopsies of lean subjects were collected during cholecystectomy, 3 SAT 
and/or VAT biopsies were collected during colonic resection for diverticular disease, 3 SAT and 
/or VAT biopsies during laparoscopic fundoplication, 2 SAT and /or VAT biopsies during 
umbilical hernia repair and 1 SAT and /or VAT biopsies during rectal prolapse surgery. Lean 
subjects displayed a mean value of 48 ± 12 years old (range 21-64 years), BMI of 24 ± 2 
Kg/m
2
 (range 20-26), fasting blood glucose of 5 ± 0,7 mmol/l (range 4,7-6,6). Among lean 
subjects 1 was affected by hypertension and 1 by dyslipidemia. When compared with the 3 
groups of obese patients, BMI resulted, significantly lower in lean subjects (p < 0,00001); 
mean value of age was not different between lean subjects and ob pre-T2DM and ob T2DM, 
while it was higher in lean when compared to ob N (p < 0,02); mean value of fasting blood 
glucose of lean subjects was comparable to that of ob N, while it was lower in respect to ob 
pre-T2DM (p < 0,01) and ob T2DM groups (p < 0,00001) (data not show).  
 
 
 
 
 
 
Table VI. Demographic, anthropometrics and metabolic parameters of lean patients and obese patients 
after weight loss (ob WL) analyzed by AT biopsies collection. BMI: Body Mass Index. Hyp: blood 
hypertension. DLP: dyslipidemia. OSAS: obstructive sleep apnea syndrome. BMI: Body Mass Index. EBMIL: 
excess BMI loss. Results were reported as means ± DS; statistical analysis was performed by paired Student’s t-
test. 
 
Nine SAT and VAT biopsies of obese patients after weight loss were collected during 
cholecystectomy, while the others 32 SAT biopsies were collected during plastic surgery. 
Weight loss (WL) was obtained in 23 patients by laparoscopic sleeve gastrectomy, in 9 patients 
by gastric banding, in 1 patient by duodenal switch, in 1 patient by intragastric balloon and in 7 
patients by caloric restriction and physical activity. Ob WL patients displayed a mean value of 
 lean 
 
(n =18) 
  ob WL      
 
(n = 41) 
Sex (F/M) 11/7 33/8 
Age (years) 48 ± 12 47 ± 12 
HYP (n; %) 1 (5%) 5 (12%) 
DLP  (n; %) 1 (5%) 7 (17%) 
OSAS  (n; %) 0 (0%) 0 (0%) 
BMI (Kg/m2)  24 ± 2 31 ± 6 
Blood Glucose (mmol/l) 5 ± 0,7 5 ± 0,7 
%EBMIL - 74 ± 25 
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47 ± 12 years old (range 21-69), BMI of 31 ± 6 Kg/m
2 
(range 22,5-48), percentage of excess 
BMI loss (% EBMIL) of 74 ± 25 % (range 23-119), fasting blood glucose of 5 ± 0,7 mmol/l 
(range 3,4-6,4). Among ob WL patients, 5 were affected by hypertension and 7 by 
dyslipidemia. Before WL 6 patients were diabetics and after WL 5 have experienced a 
remission of T2DM and only 1 remained diabetic. When compared with the 3 groups of obese 
patients, BMI resulted significantly lower in ob WL patients (p < 0,00001); mean value of age 
was not different between ob WL patients and ob pre-T2DM, while was higher in ob WL when 
compared to ob N (p < 0,01) and lower in ob WL when compared to ob T2DM (p < 0,05); 
mean value of fasting blood glucose of ob WL patients was comparable to mean value of 
fasting blood glucose of ob N, while it was lower than that of ob pre-T2DM (p < 0,05) and ob 
T2DM (p < 0,00001) (data not show). 
5.1.2 Histology and Immunohistochemistry 
We performed immunohistochemical analysis (IHC) of SAT and VAT samples from 6 lean 
subjects  and from 15 obese patients (5 ob N, 5 ob pre-T2DM, 5 ob T2DM) whose main 
demographic, anthropometrics and metabolic parameters are reported in Table VII.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table VII. Demographic, anthropometrics and metabolic parameters of lean patients and obese patients 
analyzed by IHC. BMI: Body Mass Index. Hyp: blood hypertension. DLP: dyslipidemia. OSAS: obstructive sleep 
apnea syndrome. BMI: Body Mass Index. HOMA-IR: Homeostasis Model Assessment. T-CHL: total cholesterol. 
HDL: High Density Lipoproteins. LDL: Low Density Lipoproteins. TGL: triglycerides. hs-PCR: High sensitive C-
Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor Necrosis Factor-alpha. Results were reported as means ± DS; 
statistical analysis was performed by paired Student’s t-test. 
 Lean 
 
 
(n = 6) 
ob N 
 
 
(n = 5) 
ob pre-
T2DM 
 
(n = 5) 
ob 
T2DM 
 
(n = 5) 
p 
 
lean 
 vs   
ob N 
p 
 
ob N 
 vs   
ob pre-
T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-
T2DM 
vs  
ob T2DM 
 
Sex (F/M) 2/4 4/1 4/1 2/3 - - - - 
Age (years) 55±6 42 ±9 56 ± 9 44 ± 13 <0,05 <0,05 ns <0,01 
HYP (n/tot goup) 2/6 1/5 4/5 4/5 - - - - 
DLP (n/tot goup) 0/6 3/5 4/5 5/5 - - - - 
OSAS (n/tot goup) 0/6 0/5 3/5 1/5 - - - - 
BMI (Kg/m2) 23,7±1,3 54 ± 19 47 ± 6 57 ± 9 <0,01 ns ns 0,05 
Waist(cm) - 127 ± 19  129 ± 14 154 ± 16 - ns 0,06 <0,05 
Blood Glucose (mmol/l) 5,2±1,02 4,8±0,18 5,6 ± 0,9 10 ± 4,3 ns ns <0,05 <0,05 
Insulin (mU/l) - 15 ± 9  23 ± 18 - - ns - - 
HOMA-IR - 3,3 ± 1,9 5,9 ± 5,7 - - ns - - 
HbA1c (mmol/mol) - - - 73 ± 26 - - - - 
T-CHL (mg/dl) - 193 ± 27 202 ± 47 225 ± 47 - ns ns ns 
HDL (mg/dl) - 51 ± 9 50 ± 13 41 ± 8 - ns ns ns 
LDL (mg/dl) - 123± 17 128 ± 35 154 ± 38 - ns ns ns 
TGL (mg/dl) - 93 ± 26 120 ± 62 223 ± 77 - ns <0,01 <0,05 
hsPCR (mg/l) - 4,3 ±2,6 9,1 ± 8,4 9,3 ± 1,8 - ns <0,01 ns 
TNF-α (ng/l) - 8,4± 2,9 10 ± 4,5 10,7±2,9 - ns ns ns 
IL-6 (ng/l) - 3,2 ±1,5 3,1 ± 1,6 4,5 ± 2,3 - ns ns ns 
Leptin (ug/l) - 33 ± 17 43 ± 8 38 ± 18 - ns ns ns 
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5.1.2.1 Adipocyte Size 
In SAT and VAT samples, as showed in Figure 11, median adipocyte area (μm2) was lower in 
lean patients compared to obese patients, regardless of group division (p < 0,001).   
In SAT, adipocyte area of ob N was significantly smaller than that of ob pre-T2DM (p < 0,01) 
and of ob T2DM (p < 0,001) while no significant differences were present between adipocyte 
area of ob pre-T2DM and ob T2DM. In VAT, adipocyte area of ob N was significantly smaller 
than that of ob T2DM (p < 0,001) and adipocyte area of ob pre-T2DM was significantly 
smaller than that of ob T2DM (p < 0,01), while no significant differences were between 
adipocyte area of ob N and ob pre-T2DM. Taken together these data show that among obese 
patients, there is an increasing trend in adipocytes area from ob N to ob T2DM both in SAT and 
in VAT showing that adipocytes coming from ob T2DM patients are largest in both depots. 
 
Figure 11. Adipocyte size (μm2) in subcutaneous, A, (SAT) and visceral, B, (VAT) adipose tissue in the 4 groups of 
patients: lean (n=6), obese normoglycemic (ob N=5), obese pre-diabetic (ob pre-T2DM= 5) and obese diabetic (ob 
T2DM=5) (*p <0,01; **p<0,001). C, adypocite size in SAT (indicated by white box) vs VAT (indicated by grey box) in 
the 4 groups of patients (*p <0, 01; **p<0,001). Representative SAT (D) and VAT (E) sections from lean, ob N, ob pre-
T2DM and ob T2DM subjects stained with Monoclonal Mouse Anti-Human CD31, Clone JC70A. Adipocyte size was 
measured in at least 10 random fields at 20X magnification (at least 200 random adipocytes per tissue biopsy were 
counted). Median adipocyte area was calculated in each group. Results are reported as box plot graph with median, 
minimum and maximum values; statistical analysis was performed by Mann-Whitney test.  
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When we compared SAT and VAT we observed that in all 4 groups considered adipocyte area 
is larger in SAT than in VAT (p < 0,01 for lean subjects, p < 0,001 for obese patients) 
according to what previously described in the literature, considering obese patients regardless 
the presence of metabolic complications.  
5.1.2.2 Capillary Density 
Regarding to the capillary density quantification (Figure 12), we observed that lean subjects 
displayed an higher number of vessels per mm
2
 both in SAT and in VAT compared to obese 
patients (p < 0,001) despite an higher degree of variability observed in the VAT capillaries’ 
number. On the contrary we did not showed any significant variation in SAT and VAT 
vascularization between the 3 obese patients group (ob N, ob pre-T2DM and ob T2DM). 
 
Figure 12. Capillary density (n° capillaries/mm
2
) in subcutaneous, A, (SAT) and visceral, B, (VAT) adipose 
tissue in the 4 groups of patients: lean (n=6), obese normoglycemic (ob N=5), obese pre-diabetic (ob pre-T2DM= 
5) and obese diabetic (ob T2DM=5) (**p<0,001). C, capillary density in SAT (indicated by white box) vs VAT 
(indicated by grey box) in the 4 groups of patients (*p <0, 01; **p<0,001). Representative VAT (D) sections from 
lean and ob pre-T2DM subjects stained with Monoclonal Mouse Anti-Human CD31, Clone JC70A. Capillary 
density was measured in at least 10 random fields at 20X magnification (at least 200 random adipocytes per tissue 
biopsy were counted). The value for each patient was the average number of lumens per field. Results are reported 
as box plot graph with median, minimum and maximum values; statistical analysis was performed by Mann-
Whitney test.  
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Moreover, we found that VAT is more vascularized than SAT both in lean and in obese patients 
(p < 0, 01 for lean, p < 0,001 for obese). An interesting data to be emphasized is that, while the 
number of vessels per mm
2 
decreased of 40% between lean and obese SAT, the parallel 
reduction resulted higher in VAT, amounting to the 54, 5%. 
To further explore TA vascularization we calculated the number of capillaries per adipocyte 
and we observed that both in SAT than in VAT lean group displayed a ratio slightly higher that 
obese groups; moreover there was an increasing trend in this ratio in obese patients with 
increasing metabolic complications. Indeed, in SAT the number of vessels per adipocyte was 
significantly higher in ob pre-T2DM and in ob T2DM compared to ob N (p< 0, 0001), while no 
differences were noted between ob pre-T2DM and ob T2DM. Similarly in VAT there was a 
higher number of vessels per adipocyte in ob pre-T2DM (p<0, 05) and in ob T2DM (p<0, 
0001) compared to ob N. Moreover, there was a significant difference also between ob pre-
T2DM an ob T2DM (p<0, 05).  
 
Figure 13. Number of capillaries per adipocyte in subcutaneous, A, (SAT) and visceral, B, (VAT) 
adipose tissue in the 4 groups of patients: lean (n=6), obese normoglycemic (ob N=5), obese pre-diabetic 
(ob pre-T2DM= 5) and obese diabetic (ob T2DM=5) (*p<0, 05; **p<0, 01; ***p<0,001). C, number of 
vessels per adipocyte in SAT (indicated by white box) vs VAT (indicated by grey box) in the 4 groups of 
patients. Median adipocyte area supplied by a single capillary in SAT, D, and VAT, E, in the 4 groups 
of patients: lean (n=6), ob N (n=5), ob pre-T2DM (n= 5) and ob T2DM (n=5) (**p<0,001). F, number of 
vessels per adipocyte in SAT (indicated by white box) vs VAT (indicated by grey box) in the 4 groups of 
patients (*p<0, 01; **p<0,001). Results are reported as box plot graph with median, minimum and 
maximum values; statistical analysis was performed by Mann-Whitney test.  
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Lean patients showed an elevated ratio (vessels /adipocyte) both in SAT and in VAT in 
comparison with ob N group (p < 0, 01) whereas no differences were found with other obese 
groups. No significantly differences appeared comparing SAT and VAT depots. Finally, we 
calculated the median adipocyte area supplied by a single capillary and we did not find 
significantly differences in the 3 obese groups, whereas both in SAT and in VAT of lean patients 
a single capillary vessel supplies a smaller adipocyte area compared to obese patients (p < 
0,001) (Figure 13). When SAT and VAT samples were compare in each group, we observed that 
a single capillary vessel supplies a higher adipocyte area in SAT than in VAT (p < 0, 01 for lean 
and p < 0,001 for obese). Median adipocyte size was positive correlated with BMI (R = 0,7 in 
SAT; R = 0,5 in VAT; p<0,05) and IL-6 ( R = 0,5 in SAT; R = 0,6 in VAT; p<0,05) both in SAT 
and in VAT; with waist in SAT (R = 0,7; p<0,05) and in VAT, median adipocyte size, negatively 
correlated with capillary density (R = -0,6; p<0,05) as showed in Figure 14. 
 
Figure 14. Correlation between adipocyte area and clinical parameters. Median adipocytes area positively 
correlated with BMI and IL-6 both in subcutaneous (SAT) (R=0, 7 and R= 0, 5 respectively), A-B, and in 
visceral (VAT) (R=0, 5 and R=0, 6 respectively), D-E, adipose tissue. In SAT median adipocyte area positively 
correlated with waist, C, (R=0, 7). In VAT median adipocyte area was inversely correlated with capillary 
density, E, (R=-0, 6). Spearman's rank correlation was performed and a value of p<0,05 was considered 
significant. 
SAT
Adipocyte area – BMI Adipocyte area – IL-6 Adipocyte area – waistA B C
VAT
Adipocyte area – BMI Adipocyte area – IL-6 Adipocyte area – capillary/mm2D E F
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In conclusion, we showed that adipocytes area is smaller in lean than in obese patients both in 
SAT than in VAT. In obese patients, there is an increasing adipocytes area that parallel the 
worsening of metabolic conditions. Moreover, VAT resulted more vascularized, quantifying the 
number of capillaries, compared to SAT. Both SAT and VAT of lean subjects appeared more 
vascularized than AT depots from obese subjects. In obese patients the capillary density and the 
median adipocytes area supply by a single vessel did not differ if we considered T2DM 
progression among groups. In these 3 groups the only difference, regarding vascularization, 
consists in the ratio number of capillary per adipocyte that increases with T2DM progression in 
both depots.  
5.1.3 Flow Cytofluorimetric Analysis of Stromal Vascular Fraction  
SAT samples of 24 ob N, 18 ob pre-T2DM, 23 ob T2DM, 5 lean normal weight and 
normoglycemic subjects (18.5 < BMI < 24,9 kg/m2) and 17 obese patients  underwent to a 
relevant  weight loss ( ob WL), corresponding to at least 10% of body weight, were used to 
isolate SVF and to perform multiparameter flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table VIII. Demographic, anthropometrics and metabolic parameters of obese patients analyzed by flow 
cytometry of SAT biopsies. BMI: Body Mass Index. Hyp: blood hypertension. DLP: dyslipidemia. OSAS: 
obstructive sleep apnea syndrome. BMI: Body Mass Index. HOMA-IR: Homeostasis Model Assessment. T-CHL: 
total cholesterol. HDL: High Density Lipoproteins. LDL: Low Density Lipoproteins. TGL: triglycerides. hs-PCR: 
High sensitive C-Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor Necrosis Factor-alpha. Results were 
reported as means ± DS; statistical analysis was performed by paired Student’s t-test. 
 ob N 
 
 
(n = 24) 
ob pre-
T2DM 
 
(n = 18) 
ob T2DM 
 
 
(n = 23) 
p 
 
ob N 
 vs   
ob pre-T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-T2DM 
vs  
ob T2DM 
 
Sex (F/M) 19/6 15/3 15/9    
Age (years) 40 ±11 47 ± 11 52 ± 11 <0,05 <0,001 ns 
HYP  (n/tot goup) 13/24 9/18 21/23    
DLP (n/tot goup) 13/24 11/18 20/23    
OSAS (n/tot goup) 3/24 7/18 11/23    
BMI (Kg/m2) 48 ± 10 48 ± 8 49 ± 9 ns ns ns 
Waist(cm) 131 ± 15  135 ± 12 138 ± 16 ns ns ns 
Blood Glucose 
(mmol/l) 
4,9 ± 0,4 5,9 ± 0,7 8,8 ± 2,8 <0,00001 <0,0000 <0,0001 
Insulin (mU/l) 17 ± 12 32 ± 27 - <0,05 - - 
HOMA-IR 3,7 ± 2,8 8,7 ± 7,8 - <0,01 - - 
HbA1c (mmol/mol) - - 63 ± 17 - - - 
T-CHL (mg/dl) 188 ± 28 201 ±  34 193 ± 51 ns ns ns 
HDL (mg/dl) 45 ± 12 48 ± 11 42 ± 12 ns ns ns 
LDL (mg/dl) 118 ± 28  124 ± 33 121 ± 42 ns ns ns 
TGL (mg/dl) 135 ± 69 154 ± 87 175 ± 82 ns ns ns 
hsPCR (mg/l) 5,7 ± 3,7 8,1 ± 4,9 8,2 ± 2,5 ns <0,05 ns 
TNF-α (ng/l) 8,5 ± 2,3 8,5 ± 2,7 10,3 ± 3 ns <0,05 ns 
IL-6 (ng/l) 3,3 ± 1,5 3,7 ± 1,5 4 ± 2,5 ns ns ns 
Leptin (ug/l) 41 ± 16 42 ± 13 39 ± 17 ns ns ns 
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VAT samples of 25 ob N, 25 ob pre-T2DM, 30 ob T2DM and of 10 lean normal weight and 
normoglycemic subjects (18.5 < BMI < 24, 9 kg/m2) subjects were used to isolate SVF and to 
perform multiparameter flow cytometry. Main demographic, anthropometrics and metabolic 
parameters of obese groups are reported in Tables VIII and IX.  
Table IX. Demographic, anthropometrics and metabolic parameters of obese patients analyzed by flow 
cytometry of VAT biopsies. BMI: Body Mass Index. Hyp: blood hypertension. DLP: dyslipidemia. OSAS: 
obstructive sleep apnea syndrome. BMI: Body Mass Index. HOMA-IR: Homeostasis Model Assessment. T-CHL: 
total cholesterol. HDL: High Density Lipoproteins. LDL: Low Density Lipoproteins. TGL: triglycerides. hs-PCR: 
High sensitive C-Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor Necrosis Factor-alpha. Results were 
reported as means ± DS; statistical analysis was performed by paired Student’s t-test. 
 
 
5.1.3.1 Glucose Impairment Early Affects Adipose Stem Cells in Obesity. 
SAT and VAT derived adipose stem cells (ASCs) were quantified ex vivo as CD34+CD31-
CD45- cells by FACS analysis in normal weight lean subjects, ob N, ob pre-T2DM and ob 
T2DM patients. Freshly extracted SVFs obtained from AT specimens were analyzed and on the 
basis of forward/side scatter morphological gate was considered in order to exclude cellular 
fragments, aggregates and immune cells, and cell positive for CD45 staining (Figure 15).  
 ob N 
 
 
(n = 25) 
ob pre-
T2DM 
 
(n = 25) 
ob T2DM 
 
 
(n = 30) 
p 
 
ob N 
 vs   
ob pre-T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-T2DM 
vs  
ob T2DM 
 
Sex (F/M) 19/6 15/3 15/9    
Age (years) 38 ±11 47 ± 11 52 ± 10 <0,05 <0,00001 ns 
HYP (n/tot goup) 13/25 9/25 21/30    
DLP (n/tot goup) 13/25 11/25 20/30    
OSAS (n/tot goup) 3/25 7/25 11/30    
BMI (Kg/m2) 48 ± 10 49 ± 9 49 ± 9 ns ns ns 
Waist(cm) 130 ± 14  135 ± 11 136 ± 16 ns ns ns 
Blood Glucose 
(mmol/l) 
4,9 ± 0,4 5,8 ± 0,6 9,8 ± 4,3 <0,00000 <0,0000 <0,00001 
Insulin (mU/l) 17 ± 11 30 ± 24 - <0,05 - - 
HOMA-IR 3,7 ± 2,5 7,9 ± 6,9 - <0,005 - - 
HbA1c (mmol/mol) - - 66 ± 20 - - - 
T-CHL (mg/dl) 185 ± 28 196 ± 40 194 ± 46 ns ns ns 
HDL (mg/dl) 45 ± 11 48 ± 12 42 ± 13 ns ns ns 
LDL (mg/dl) 115 ± 28  122 ± 43 122 ± 39 ns ns ns 
TGL (mg/dl) 130 ± 66 153 ± 97 176 ± 81 ns <0,05 ns 
hsPCR (mg/l) 10 ± 21 8,2 ± 5,3 7,9 ± 2,8 ns ns ns 
TNF-α (ng/l) 8,6 ± 3,3 8,6 ± 3,3 9,8 ± 3 ns ns ns 
IL-6 (ng/l) 3,7 ± 2,8 3,5 ± 1,3 4,2 ± 2,6 ns ns ns 
Leptin (ug/l) 41 ± 15 44 ± 16 37 ± 16 ns ns ns 
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Figure 15. Dot plot of FSC (forward scatter) against SSC (side scatter) on a linear scale. 
Morphologic localization of CD34 + and CD45 + cells. 
 
As shown in Figure 16, SAT of ob N patients appears to be enriched of ASCs in comparison 
with lean subjects, although the high variability of data from normal weight controls. SAT 
ASCs obtained from ob pre-T2DM and ob T2DM patients were lower than those obtained from 
ob N patients (respectively 28.9 % (10.1-43.9%), 31.2% (10.5-44.7%) vs 40.6% (19-78.7%), 
p<0.05). Interestingly, after significant weight loss SAT further increases its content of 
adipogenic precursors (62.4% 46.7-87.6%) in comparison with both lean subjects (11.5% 0.3-
47.3%; p<0, 05) and obese patients (p<0,001). Consensually in VAT a clear decreasing trend of 
ASCs number in ob pre-T2DM and ob T2DM in respect to ob N patients was observed 
(p<0,001). In all obese patients VAT displays a significantly higher number of ASCs in 
comparison with control (Ob N 47.4% (19.1-64%), Ob preT2DM 42% (21.6-58.9%) vs lean 
29.4% (9.6-40.7%); p<0,001; Ob T2DM 39.6% (25.1-59.2%) vs lean 29.4% (9.6-40.7%); 
p<0.05); it is worth noting that control group has a high sample number (n=10) and a relatively 
low variability: VAT collection is easier in normal weight patients and provides a higher 
amount of tissue in comparison with SAT. Comparing the two deposits, VAT contains a higher 
number of ASCs in respect of SAT in all obese groups while controls do not present 
differences; moreover it is to underlie the major decrease of ASCs number of ob pre-T2DM 
and ob T2DM in respect to ob N patients in SAT (ob pre T2DM vs ob N reduction of 28.8%; 
ob T2DM vs ob N reduction of 23.2%) than in VAT (ob pre T2DM vs ob N reduction of 11.4%; 
ob T2DM vs ob N reduction of 16.5%).  
Even if ob T2DM and ob pre T2DM were older than ob N, we didn’t found any correlation 
between ASCs and age nor in SAT neither in VAT (data not show). Moreover, adipogenic 
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precursors were not correlated with anyone of anthropometric and metabolic parameters 
considered in our population. 
 
Figure 16. Median percentage of CD45-CD34+CD31- in subcutaneous, A, (SAT) and visceral, B, (VAT) 
adipose tissue in the 5 groups of patients: lean, obese normoglycemic (ob N), obese pre-diabetic (ob pre-T2DM), 
obese diabetic (ob T2DM) and, only in SAT, obese after weight loss (ob WL), (*p<0, 05; **p<0,001). C, Median 
percentage of CD45-CD34+CD31- in SAT (indicated by white box) vs VAT (indicated by grey box) in the first 4 
groups of patients. Representative SAT (D) and VAT (E) dot plots of analysis of CD34-31-, CD34-31+, 
CD34+31-, CD34+31+ immunologic subpopulations from lean, ob N, ob pre-T2DM, ob T2DM and ob WL 
subjects. Numbers of AT samples analyzed per each group are reported under every box. Results are reported as 
box plot graph with median, minimum and maximum values; statistical analysis was performed by Mann-
Whitney test.  
 
ASCs phenotype was also analyzed in the CD34+ CD31- immunological gate. CD90, CD73 
and CD44 result similarly expressed by ASCs of obese patients (see Table X). A greater 
percentage of SAT derived ASCs express CD90 than VAT in all groups. 
CD105 is a mesenchymal marker that is believed to be always expressed by mesenchymal stem 
cells (MSCs). Differently, only 30-70% of ASCs both in lean and obese subjects expresses 
CD105 without differences among groups (Figure 17, A-B-C). In obese but not in lean subjects 
VAT ASCs display a significantly higher expression of CD105 in comparison with SAT. 
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CD271 represents an additional marker used to characterize a subpopulation of MSC in bone 
marrow; it was evaluated only in obese patients due to the limited material available in lean 
subjects. ASCs from obese patients showed a high expression of CD271 (Table XI) with the 
major percentage in VAT (Figure 18, D-E-F). 
 
Table X. Percentage of CD34+CD31- cells expressing the mesenchymal markers CD90, CD73 and 
CD44 in SAT and VAT from normoglycemic (Ob N), prediabetic (Ob preT2D) and diabetic obese patients. 
Data are reported as median and minimum-maximum values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XI. Percentage of CD34+CD31- cells expressing the mesenchymal markers CD105 and 
CD271 in SAT and VAT from lean, normoglycemic (ob N), prediabetic (ob preT2D) and diabetic obese 
patients (ob T2DM). SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue. Data are reported as 
median and minimum-maximum values. 
CD34+CD31- CD90+ % (min-max) CD73+ % (min-max) CD44+ % (min-max) 
SAT VAT SAT VAT SAT VAT 
Ob N 97.7 (82.3-99.7) 95.5 (70-98.8) 97.8 (87.9-99.5) 94.3 (83.7-98.6) 94.1 (90-98.2) 93.6 (90.2-99.3) 
Ob preT2D 99 (87.7-99.7) 95 (59-99.5) 96.3 (88.7-97.8) 93.9 (82.8-99.2) 94 (92.3-96.8) 88.9 (61.1-97) 
Ob T2DM 91.2 (74.8-100) 95.7 (65.7-99.7) 92.9 (85.3-96.2) 93.9 (81.8-97.8) 99.1 (94.5-99.9) 93.6 (67.8-98.4) 
CD34+CD31- CD105+ % (min-max) CD271+ % (min-max) 
SAT VAT SAT VAT 
Lean 42.2 (24.9-59.4) 48.9 (29.7-87.2) - - 
Ob N 29.3 (1.8-71.9) 62.6 (6.5-88.8) 37.3 (11.6-54.3) 70.5 (47.8-92.7) 
Ob preT2D 42 (4.2-76.8) 63.4 (32.3-88.4) 42.3 (22.7-45.5) 68.2 (38.7-96.7) 
Ob T2DM 29.7 (2.7-75.9) 66.8 (7.9-79.2) 28.9 (8.5-60.1) 55.1 (23.1-80.4) 
Ob WL 20.9 (4.5-60.1) - 28.3 (7.5-55.9) - 
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Figure 17. Median percentage of CD34+CD31- cells expressing CD105+ in subcutaneous, A, (SAT) and 
visceral, B, (VAT) adipose tissue in the 5 groups of patients: lean, obese normoglycemic (ob N), obese pre-
diabetic (ob pre-T2DM), obese diabetic (ob T2DM) and, only in SAT, obese after weight loss (ob WL), (*p<0, 
05). C, Median percentage of  CD34+CD31- cells expressing CD105+ in SAT (indicated by white box) vs VAT 
(indicated by grey box) in the first 4 groups of patients (*p<0,05; **p<0,001). Median percentage of 
CD34+CD31- cells expressing CD271+ in SAT, D, and VAT, E in the 4 groups of patients: ob N, ob pre-T2DM, 
ob T2DM and, only in SAT, ob WL (*p<0,05).  F, Median percentage of  CD34+CD31- cells expressing CD271+ 
in SAT (indicated by white box) vs VAT (indicated by grey box) in the first 3 groups of patients (*p<0,05; 
**p<0,001). Numbers of AT samples analyzed per each group are reported under every box. Results are reported 
as box plot graph with median, minimum and maximum values; Mann-Whitney test was performed. 
 
A deep debate exists about the relationship between ASCs and pericytes in term of a common 
or distinct origin (Cai, 2011; Zimmerlin, 2012. For this reason CD146, commonly used as 
pericyte marker, has been also evaluated ex vivo in SFVs. This subpopulation represents a 
relatively high fraction of the AT SVF and the majority of the cells positive for CD146 stains 
negatively for CD34 and CD31. In VAT CD146+ cells display a similar behavior of ASCs 
being significantly higher in all obese patients with a decreasing trend within the 3 groups 
(Lean 1% (0.4-3.5); ob N 5.2% (1.7-13.7%); ob pre-T2DM 3.05% (1.3-7.6); ob T2DM 1.7% 
(0.8-8.2)). In SAT CD146+ cells have been quantified in a smaller number of obese subjects 
and not in control due to the low sample amount. In this depot we do not show differences 
among obese groups and in weight loss group (ob N 6.6% (19.3-2.6%); ob pre-T2DM 10.8% 
(3.2-11.8); ob T2DM 7.2% (2.6-11.5); Ob WL 6.5% (1-11.5)). Comparing the two AT depots, 
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SAT is enriched of CD146+ cells in respect of VAT in all obese subjects, similarly to 
endothelial precursors (see below) (Figure 18).  
 
 
Figure 18. Median percentage of CD146+ in subcutaneous adipose tissue (SAT), A, in obese 
normoglycemic (ob N), obese pre-diabetic (ob pre-T2DM), obese diabetic (ob T2DM) and obese after 
weight loss (ob WL) patients, and visceral adipose tissue(VAT), B,  in lean, ob N, ob pre-T2DM and ob 
T2DM (*p<0,05). C, Median percentage of CD146+ in SAT (indicated by white box) vs VAT (indicated 
by grey box) in the 3 groups of obese patients. Numbers of AT samples analyzed per each group are 
reported under every box. Results are reported as box plot graph with median, minimum and maximum 
values; Mann-Whitney test was performed. 
 
 
5.1.3.2 Endothelial Progenitors are progressively altered by Obesity and Overt Diabetes.  
Endothelial precursors cells (EPs) were defined as CD34+ CD31+ CD45- cells. In SAT, ob N 
EPs number increased in respect of lean subjects and was similar in ob pre-T2DM (Lean: 5.8% 
(0.6-15.5%); Ob N 17.4% (3-55.8%); Ob preT2DM 24% (4.3-41.1%); Ob T2DM 15.9% (0.8-
29.6%); Ob WL 9.5% (3.8-28.5%)), differently from what seen with ASCs percentage. 
With overt diabetes (patients from ob T2DM group) EPs decreased significantly in comparison 
with ob pre-T2DM. Interestingly after weight loss EPs revert to lean control level. In VAT EPs 
displayed the same trend of SAT-extracted precursors, although for VAT we do not have the 
possibility to analyze weight loss effect.  
A part from lean subjects, in all obese patients SAT shows a significantly higher angiogenetic 
potential than VAT as indicated by EPs quantification (Figure 19). 
EPs percentage inversely correlated with age, both in SAT than in VAT (R = -0,2; R= - 0,3 
respectively; p≤0,05) and positively correlated with BMI only in SAT (R = 0,3 R= - 0,3 
respectively; p≤0,05). No other statistically significant correlation was found between EPs 
percentage and anthropometric and metabolic parameters considered. 
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Figure 19. Median percentage of CD45-34+31+ in subcutaneus, A, (SAT) and visceral, B, (VAT) adipose tissue 
in the 5 groups of patients: lean, obese normoglycemic (ob N), obese pre-diabetic (ob pre-T2DM), obese diabetic 
(ob T2DM) and, only in SAT, obese after weight loss (ob WL), (*p<0, 05; **p<0,001). C, Median percentage of 
CD45-CD34+CD31+ in SAT (indicated by white box) vs VAT (indicated by grey box) in the first 4 groups of 
patients (*p<0, 05; **p<0,001). Numbers of AT samples analyzed per each group are reported under every box. 
Results are reported as box plot graph with median, minimum and maximum values; statistical analysis was 
performed by Mann-Whitney test. 
 
5.1.4 In vitro Evaluation of Adipogenic Potential of Stromal Vascular Fraction Obtained 
from Adipose Tissue depots. 
In vitro capacity to differentiate towards the adipogenic lineage was analyzed in the 3 obese 
groups studied (in SAT: ob N=18; ob preT2DM=15; ob T2DM=14. In VAT: ob N=20; ob 
preT2DM=25; ob T2DM=23). Main demographic, anthropometrics and metabolic parameters 
of obese groups are reported in Tables XII and XIII.  
Freshly isolated SVFs were cultured in adipogenic medium and after 9 days of culture the 
percentage of mature adipocytes cells containing large lipid droplets was measured by optical 
microscope analysis.  
SVFs obtained from SAT of ob preT2DM and, unless in a minor extent, ob T2DM derived 
ASCs display a lower adipogenic potential in comparison to ob N group (median value: 66%, 
range 25-99% in ob N; 40%, range 12-80% in ob pre-T2DM; 55%, range 12-98% in ob 
T2DM) (Figure 20).  
SVFs isolated from VAT display a lower adipogenic potential in culture conditions used which 
were not able to disclose relevant differences among the obese groups, despite the high number 
of obese patients studied (median value: 15%, range 5-70% in lean; 21%, range 5-70% in ob 
N; 22%, range 2-85% in ob pre-T2DM; 22%, range 1-85% in ob T2DM) . 
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Table. XII. Demographic, anthropometrics and metabolic parameters of obese patients in witch SAT 
samples were collected for in vitro evaluation of adipogenic potential. BMI: Body Mass Index. Hyp: blood 
hypertension. DLP: dyslipidemia. OSAS: obstructive sleep apnea syndrome. BMI: Body Mass Index. HOMA-IR: 
Homeostasis Model Assessment. T-CHL: total cholesterol. HDL: High Density Lipoproteins. LDL: Low Density 
Lipoproteins. TGL: triglycerides. hs-PCR: High sensitive C-Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor 
Necrosis Factor-alpha. Results were reported as means ± DS; statistical analysis was performed by paired 
Student’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 ob N 
 
 
(n = 18) 
ob pre-
T2DM 
 
(n = 15) 
ob T2DM 
 
 
(n = 14) 
p 
 
ob N 
 vs   
ob pre-T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-T2DM 
vs  
ob T2DM 
 
Sex (F/M) 15/5 13/2 9/5    
Age (years) 38 ±11 46 ± 10 48 ± 10 <0,05 <0,01 ns 
HYP (n/tot goup) 6/18 6/15 13/14    
DLP (n/tot goup) 11/18 8/15 13/14    
OSAS (n/tot goup) 1/18 4/15 5/14    
BMI (Kg/m2) 49 ± 12 50 ± 9 52 ± 7 ns ns ns 
Waist(cm) 129 ± 15  135 ± 14 144 ± 14 ns <0,05 ns 
Blood Glucose 
(mmol/l) 
4,9 ± 0,4 5,8 ± 0,7 11,6 ± 5,5 <0,00001 <0,00001 <0,005 
Insulin (mU/l) 18 ± 12 36 ± 26 - <0,01 - - 
HOMA-IR 4,1 ± 2,9 9,6 ± 7,7 - <0,01 - - 
HbA1c (mmol/mol) - - 71 ± 24 - - - 
T-CHL (mg/dl) 187 ± 30 197 ± 27 193 ± 49 ns ns ns 
HDL (mg/dl) 45 ± 13 48 ± 11 41 ± 14 ns ns ns 
LDL (mg/dl) 119 ± 30  121 ± 31 124 ± 43 ns ns ns 
TGL (mg/dl) 138 ± 77 155 ± 80 190 ± 79 ns <0,01 ns 
hsPCR (mg/l) 11 ± 25 7 ± 3,4 8,3 ± 3 ns <0,01 ns 
TNF-α (ng/l) 8,3 ± 2,7 8,9 ± 3,7 16,3± 24,5 ns ns ns 
IL-6 (ng/l) 2,8 ± 1 4 ± 1,2 11,5 ± 25 <0,01 ns ns 
Leptin (ug/l) 40 ± 17 46 ± 17 39 ± 15 ns ns ns 
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Table XIII. Demographic, anthropometrics and metabolic parameters of obese patients in witch VAT 
samples were collected for in vitro evaluation of adipogenic potential. BMI: Body Mass Index. Hyp: blood 
hypertension. DLP: dyslipidemia. OSAS: obstructive sleep apnea syndrome. BMI: Body Mass Index. HOMA-IR: 
Homeostasis Model Assessment. T-CHL: total cholesterol. HDL: High Density Lipoproteins. LDL: Low Density 
Lipoproteins. TGL: triglycerides. hs-PCR: High sensitive C-Reactive Protein. IL-6: Interleukin-6. TNF-α: Tumor 
Necrosis Factor-alpha. Results were reported as means ± DS; statistical analysis was performed by paired 
Student’s t-test. 
 
Percentage of mature adipocyte cells, after 9 days of culture inversely correlated with IL-6 both 
in SAT and in VAT (R = -0,3 in SAT and in VAT; p≤0,05) No other statistically significant 
correlation was found between EPs percentage and anthropometric and metabolic parameters 
considered. 
 ob N 
 
 
(n = 20) 
ob pre-
T2DM 
 
(n = 25) 
ob T2DM 
 
 
(n = 23) 
p 
 
ob N 
 vs   
ob pre-T2DM 
 
p 
 
ob N 
 vs   
ob T2DM 
 
p 
 
ob pre-T2DM 
vs  
ob T2DM 
 
Sex (F/M) 17/3 21/4 13/10    
Age (years) 42 ±8 47 ± 10 52 ± 10 ns <0,001 ns 
HYP (n/tot goup) 7/20 11/25 21/23    
DLP (n/tot goup) 11/20 14/25 20/23    
OSAS (n/tot goup) 2/20 7/25 10/23    
BMI (Kg/m2) 49 ± 11 48 ± 8 50 ± 9 ns ns ns 
Waist(cm) 128 ± 15  133 ± 12 138 ± 18 ns ns ns 
Blood Glucose 
(mmol/l) 
5,0 ± 0,3 5,7 ± 0,6 10,1 ± 4,7 <0,0001 <0,0001 <0,001 
Insulin (mU/l) 17 ± 11,5 30 ± 24 - <0,05 - - 
HOMA-IR 3,9 ± 2,8 7,8 ± 6,9 - <0,05 - - 
HbA1c (mmol/mol) - - 63,3 ± 22 - - - 
T-CHL (mg/dl) 191 ± 28 202 ± 40 192± 48 ns ns ns 
HDL (mg/dl) 48 ± 9 49 ± 12 40 ± 12 ns <0,05 <0,05 
LDL (mg/dl) 123 ± 24  127 ± 45 120 ± 40 ns ns ns 
TGL (mg/dl) 117 ± 46 159 ± 96 171 ± 73 ns <0,01 ns 
hsPCR (mg/l) 5,3 ± 3,5 8 ± 4,5 8,1 ± 2,8 <0,05 <0,01 ns 
TNF-α (ng/l) 7,7 ± 2,5 8,3 ± 3 9,7 ± 3 ns <0,05 ns 
IL-6 (ng/l) 2,9 ± 1,2 3,5 ± 1,1 4,6 ± 2,5 <0,01 <0,01 ns 
Leptin (ug/l) 41 ± 17 43 ± 16 38 ± 16 ns ns ns 
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Figure 20. In vitro evaluation of adipogenic potential of stromal vascular fraction cells in obesity. Freshly 
isolated SVFs from SAT (A) and VAT (B) of the indicated groups were grown in adipogenic medium and after 9 
days of culture percentage of differentiated cells were evaluated by optical microscope analysis (*p<0,05). C, 
percentage of differentiated cells in SAT vs VAT (*p<0, 05; **p<0,001).  In D), E) and F) representative images of 
in vitro differentiated mature adipocytes at optical microscope at day 9 of adipogenic culture. In D, image of in 
vitro differentiated mature adipocytes in SAT of an ob N; in E, image of in vitro differentiated mature adipocytes 
in SAT of an ob T2DM and in F image of in vitro differentiated mature adipocytes in VAT of an ob T2DM  Ob N: 
normoglycemic obese (SAT n= 18, VAT n= 20), ob pre-T2DM: prediabetic obese (SAT n= 15, VAT n= 25); ob 
T2DM: diabetic obese (SAT n= 14, VAT n= 23). Results are reported as box plot graph with median, minimum 
and maximum values; statistical analysis was performed by Mann-Whitney test, * p< 0.05. 
 
5.1.5 Gene Expression Profile by RT-Real Time PCR. 
We quantified the mRNA expression of several genes in SAT and VAT biopsies obtained from 
lean subjects and obese patients during surgical intervention. We observed in obese patients an 
increased expression of PPARγ, the transcription factor that mainly regulates adipogenesis and 
controls the expression of several adipose specific genes as Adiponectin (Adipo Q) and FABP4. 
Both in SAT and in VAT the ob T2DM group displayed a lower PPARγ expression in 
comparison with ob N and ob pre T2DM group suggesting a further reduction of the in vivo 
adipogenic potential and hyperplastic growth. Also the ob WL group showed a lower PPARγ 
expression as compared with that of ob N and ob pre-T2DM groups. We did not observed 
significant differences between PPARγ expression in the 2 depots analyzed neither in lean nor 
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in obese subjects (Figure 21). VEGFA expression resulted higher and more heterogeneous in 
normal weight subjects, especially in VAT, as reported in Figure 21. No significant differences 
were evident among the 3 obese groups that displayed a different degree of metabolic 
complications. The ob WL group showed a slightly increased in VEGFA expression even if 
statistically significant only when compared with ob pre-T2DM group.  
 
Figure 21. Gene expression profile in adipose tissue depots of lean subjects and obese patients. PPAR  (A, B, 
C) and VEGFA (D, E, F) expression were quantified in SAT (A, D) and VAT (B, E) biopsies of lean, obese 
normoglycemic (ob N), obese pre-diabetic (ob pre-T2DM), obese diabetic (ob T2DM) and obese after weight loss 
(ob WL) and normalized to RPLPO mRNA content. In panels C and F SAT (white plots) and VAT (grey plots) 
expressions were compared. The number of patients analyzed are reported in every plots (n=).Results were 
reported as box plot graph with median, minimum and maximum values. Statistical analysis was performed by 
Mann-Whitney test (*p<0,05;**p<0,01;***p<0,001). 
 
Focused on the expression profile of the 3 obese groups in VAT, the AT depot highly 
vascularized, (Figure 22) we observed that ob pre T2DM and ob T2DM, even if had a similar 
BMI and Leptin blood level, displayed a significant higher quantity of Leptin mRNA than ob N 
group suggesting a different adipocyte function. Moreover we observed in Figure 22 a higher 
VEGF-R2 (KDR) expression in VAT of ob-pre-T2DM compared with ob N patients; this 
increase could represent a tentative to counteract the vasculature impairment that ob-T2DM 
patients were not able to further sustain. HIF1A displayed a similar expression profile in VAT 
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of obese patients correlating with its physiological role in stimulating the angiogenic processes 
(Figure 22).  
 
 
Figure 22. Gene expression profile in VAT of obese patients characterized by different metabolic 
complications. Leptin (A), VEGF-R2 (B) and HIF1α (C) expression were quantified in VAT biopsies of obese 
normoglycemic (ob N), obese pre-diabetic (ob pre-T2DM) and obese diabetic (ob T2DM) patients and normalized 
to RPLPO mRNA content. The number of patients analyzed are reported in every plots (n=). Results were 
reported as box plot graph with median, minimum and maximum values. Statistical analysis was performed by 
Mann-Whitney test (*p<0,05;**p<0,01;***p<0,001). 
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5.2 RESULTS (2) 
5.2.1 Anthropometric and Metabolic Parameters one year after LSG 
After surgery, 180 patients completed the OGTT. 11 patients didn’t complete the test for gastric 
intolerance. In 6 patients the test was stopped earlier for the occurrence of a severe 
symptomatic hypoglycaemic event. Data analysis was performed on 180 patients who were 
able to complete the OGTT. Demographic, anthropometrics and metabolic parameters before 
and after LSG are reported in Table XIV.  
 Before After P value 
Age, year 43 ± 11 44 ± 11 / 
Female, n., % 140 (71%) / / 
Waist, cm 132 ± 16 103 ± 16 < 0.0001 
Weight, Kg 133 ± 27 92 ± 22 < 0.0001 
BMI, Kg/m
2
 47.4 ± 7.3 32.7 ± 6.4 < 0.0001 
%EBMIL / 68.4 ± 22.8 / 
Blood Glucose, mmol/l 5.4 ± 0.7 4.6 ± 0.4 < 0.0001 
Insulin, mU/l 19.9 ± 13.6 7.6 ± 5.8 < 0.0001 
HOMA-IR 4.9 ± 3.6 1.6 ± 1.4 < 0.0001 
Total Cholesterol, mg/dl 189 ± 38 180 ± 35 < 0.001 
HDL-Cholesterol, mg/dl 49 ± 13 58 ±14 < 0.0001 
Triglycerides, mg/dl 114 ± 60 77 ± 32 <0.0001 
hs-PCR, mg/l 8.9 ± 7.8 2.6 ± 3.2 <0.0001 
IL-6, ng/l 3.19 ± 2.93 2.69 ± 2.5 <0.02 
TNF-α, ng/l 8.51 ± 3.6 6.8 ± 3.48 <0.0001 
Leptina ug/L 42 ± 15 14 ± 11 <0.0001 
Table XIV Demographic, anthropometrics and metabolic parameters before and after LSG. LSG: 
Laparoscopic Sleeve Gastrectomy. BMI: Body Mass Index. EBMIL: Excess Body Mass Index Loss. HOMA-IR: 
Homeostasis Model Assessment.  LDL: Low Density Lipopreteins. HDL: High Density Lipoproteins. Hs-PCR: 
High sensitive C-Reactive Protein. IL-6: Interleukin-6.  TNF-α: Tumor Necrosis Factor-alpha. Paired Student’s t-
test was performed. 
 
In all patients there was a significantly weight loss, with a %EBMIL amounting to 68.4 ± 
22.8% (range 23-131%) one year after LSG. A highly significant improvement in HOMA-IR 
(4.9 ± 3.6 vs 1.6 ± 1.4; p<0.0001) and in lipid profile occurred. All inflammatory parameters 
(IL-6, TNF-α and hs-PCR) decreased significantly after weight loss. Glucose and insulin 
curves during OGTT performed before and after surgery are shown in Figure 23. Both 
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parameters and, in addition, c-peptide curve during OGTT (data not show), improved after 
surgery.  
Figure 23 Glucose (A) and insulin (B) curves during OGTT performed before and after LSG. Dotted line 
indicates values obtained before LSG and solid line values obtained after LSG. Paired Student’s t-test: *p<0.001; 
**p<0.05. 
 
5.2.2 Prevalence of OGTT-related Hypoglycaemia one year after LSG 
Before LSG, 2, 5% (5/197) of the patients experienced a hypoglycaemic event during the 3 
hour OGTT. After surgery, the proportion of patients experiencing at least one hypoglycaemic 
event increased to 30, 6% (55/180) (p<0.001) (Figure 24 A), rising to 32, 8% considering the 
six patients in whom OGTT was suspended. After LSG, no patient had a hypoglycaemic and/or 
severe hypoglycaemic episode fasting and 30 minutes after glucose load. The highest 
frequency of hypoglycaemic events and severe hypoglycaemic events were observed 150’ after 
OGTT, in 27/66 (40.9%) subjects and 9/66 (13.6%) subjects respectively (Figure 24 B). 
 
Figure 24. LSG and hypoglycaemia. Percent of patients affected by severe hypoglycaemia (A) and their 
distribution (B) during OGTT before (grey) and after (black) LSG. *p<0.001 
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5.2.3 Anthropometric and Metabolic Parameters, before and one year after LSG, in 
Patients With and Without Hypoglycaemic Events 
We then divided our population in two groups: patients with (Hip) and without (N-Hip) a 
hypoglycaemic event after LSG (blood glucose levels ≤ 2.7 mmol/L). Baseline characteristics 
of these two groups were analysed in Table XV.  
  Without  
hypoglyceamia 
With 
hypoglyceamia 
P value 
 
Age, year 
 
46±10 
 
40±11 
 
0.001 
Waist, cm 134±16 130±16 n.s. 
Weight, Kg  136±29 128±22 0.05 
BMI, Kg/m
2 
48.4±7.9 46±5.7 0.02 
Blood glucose, mmol/l  5.5±0.7 5.2±0.6 0.09 
Insulin, mU/L 19.4±14.2 22.3±13.3 n.s 
HOMA-IR 4.8±3.8 5.3±3.6 n.s. 
Total Cholesterol, mg/dl 193 ± 39 184 ± 36 n.s. 
LDL-Cholesterol, mg/dl 122±35 114±31 n.s. 
HDL-Cholesterol, mg/dl 50±13 46±16 0.05 
Triglycerides, mg/dl 109±59 132±65 0.02 
hs-PCR, mg/l 9.1±8.1 8.9±7.5 n.s. 
IL-6, ng/l 3.0±1.8 3.7±4.7 n.s. 
TNF-α, ng/l 8.6±4 8.5±3 n.s. 
Leptina ug/L 41,9±15.9 41.6±15.8 n.s. 
 
Table. XV: Baseline characteristics of patients with and without a hypoglycaemic event after LSG (blood 
glucose levels ≤ 2.7 mmol/l). LSG: Laparoscopic Sleeve Gastrectomy. BMI: Body Mass Index. HOMA-IR: 
Homeostasis Model Assessment. LDL: Low Density Lipopreteins. HDL: High Density Lipoproteins. Hs-PCR: 
High sensitive C-Reactive Protein. IL-6: Interleukin-6.  TNF-α: Tumor Necrosis Factor-alpha. Unpaired Student’s 
t-test was performed. 
 
There was no difference between the two groups in terms of waist, fasting blood glucose, 
plasma insulin, HOMA-IR, total-cholesterol, LDL-cholesterol, hs-PCR, IL-6, TNF-α and 
leptina. Hip patients were, at baseline, younger than N-Hip patients (40±11 yrs vs 46±10 yrs; 
p<0,001), with a lower weight, Kg, and BMI, Kg/m
2
, (128±22 vs 136±29;   46±5.7 vs 
48.4±7.9; p<0,05) and with a worse lipid profile; indeed, Hip patients had lower HDL 
cholesterol, mg/dl, and higher triglycerides, mg/dl, compared to N-Hip (46±16 vs 50±13 and 
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132±65 vs 109±59 respectively; p<0,05). Blood glucose and plasma insulin curves after OGTT 
before and after LSG in these two groups are shown in Figure 25 A-B.  
 
Figure. 25 Glucose (A) and insulin (B) curves during OGTT performed before LSG in patients with (Hip) 
and without (NHip) hypoglycaemic events. Dotted line indicates NHip patients and solid line values obtained in 
Hip patients. There are no significant differences. Unpaired Student’s t-test was performed; p<0, 05. 
 
Glucose AUC before surgery was significantly lower in patients with hypoglycaemic events 
after LSG compared to patients without hypoglycaemic events after LSG (glucose AUC Hip vs 
NHip: 1278±246  vs 1355±222 mmol/L/h, p=0.05); while insulin AUC before surgery did not 
differed between the two groups (insulin AUC Hip vs NHip: 17529 ± 8935 vs 15735 ± 9206 
mU/L/h, p= 0.23). 
 
 
 
Figure 26 Glucose (A) and insulin (B) curves during OGTT performed after LSG in patients with (Hip) 
and without (NHip) hypoglycaemic events. Dotted line indicates NHip patients and solid line values 
obtained in Hip patients. Unpaired Student’s t-test was performed; *p<0, 0001; **p<0,005. Unpaired Student’s 
t-test was performed.  
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Considering the results of the OGTT performed one year after LSG, patients with a 
hypoglycaemic event after LSG had significantly lower levels of  blood glucose from fasting 
state and during all OGTT (Figure 26, A). Insulin plasma levels were higher at 15, 30, 60 
minutes after glucose load and lower at 150 minutes after glucose load in Hip patients (Figure 
26, B). A similar pattern has been observed for c-peptide levels (data not shown). Glucose 
AUC after surgery was lower in patients with hypoglycaemic events (887±179 vs 1135±666 
mmol/L/h, p<0.05), whereas insulin AUC was not different (11150±4974 vs 10218±6741 
mU/L/h, p<=0, 38) compared to NHip patients. 
Table XVI Anthropometrics and metabolic parameters after LSG in patients with and without 
hypoglycaemic events. LSG: Laparoscopic Sleeve Gastrectomy. BMI: Body Mass Index. EBMIL: Excess Body 
Mass Index Loss. HOMA-IR: Homeostasis Model Assessment.  LDL: Low Density Lipoproteins. HDL: High 
Density Lipoproteins. Hs-PCR: High sensitive C-Reactive Protein. IL-6: Interleukin-6.  TNF-α: Tumor Necrosis 
Factor-alpha. Unpaired Student’s t-test was performed. 
 
Patients experiencing hypoglycemic events after surgery had a significantly higher weight loss 
than patients without events (%EBMIL: 80±20 vs 62±21 %; p<0.0001) and a lower waist 
circumference (95±13 vs 107±16 cm; p<0.0001), weight (83±17 vs 97±22 Kg, p<0, 0001), 
BMI (29±4.8 vs 34±6.3 Kg/m
2
) and leptin (9.7±6.7 vs 16.2±12.9 ug/l, p<0, 0001). Moreover, 
Hip had lower plasma levels of hs-PCR compared to NHip (1.7±2.7 vs 3.0±3.5 mg/l) as 
  Without  
hypoglyceamia 
With 
hypoglyceamia 
P value 
Waist, cm 107±16 95±13 0.0001 
Weight, Kg  97±22 83±17 0.0001 
BMI, Kg/m
2 
34±6.3 29±4.8 0.0001 
%EBMIL 62±21. 80±20 0.0001 
Blood glucose, mmol/l  4.7±0.4 4.4±0.4 0.0001 
Insulin, mU/L 7.9±5.6 7.4±6.9 0.02 
HOMA-IR 1.7±1.2 1.5±1.7 n.s. 
Total Cholesterol, mg/dl 184 ± 35 175 ± 36 n.s. 
LDL-Cholesterol, mg/dl 110±32 103±33 n.s. 
HDL-Cholesterol, mg/dl 59±14 57±12 n.s 
Triglycerides, mg/dl 77±31 77±34 n.s 
hs-PCR, mg/l 3.0±3.5 1.7±2.7 0.009 
IL-6, ng/l 2.7±2.5 2.7±2.8 n.s. 
TNF-α, ng/l 7.0±3.6 6.4±3.5 n.s. 
Leptin ug/L 16.2±12.9 9.7±6.7 0.0001 
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showed in Table XVI. The delta weight and delta BMI was higher in Hip than in NHip group 
one year after the operation. 
5.2.4 Predictors of Hypoglycaemic Events before Surgery 
In order to find the independent predictors of the occurrence of a hypoglycaemic event after 
surgery, we considered  all parameters significantly different between Hip and NHip subjects 
before LSG, included fasting blood glucose  and glucose levels 120' after glucose load because 
they were lower in Hip than in NHip subjects even if no significantly (p=0,09 and p=0,06). The 
independent predictors were investigated with the use of a multiple logistic regression analysis 
model (see Statistical Analysis).  
Low age (p<0, 05), low fasting blood glucose levels (p<0, 05), and high triglycerides levels 
(p<0, 01) before LSG, were found to be independent predictors of the occurrence of a 
hypoglycaemic events after surgery (r
2
=0,131) (Table XVII) 
 
 
Table XVII: Multivariate prediction of hypoglycaemic events after LSG (blood glucose levels ≤ 2.7 mmol/l). r2 = 
0.13. The occurrence of hypoglycaemia was used as the dependent variable. Sex (male =0; female =1), age, BMI 
before surgery, and the baseline variables found to have a significance difference between patients with a without 
hypoglycaemic events after surgery were entered as independent variables in the multiple regression analysis. 
 
 
Indepent variables Correlation Coefficents P value 
 
Age, years 
 
 
-0.057 
 
0.002 
BMI, Kg/m2 
 
0.063 n.s. 
Fasting BG, mmol/l 
 
-0.711 0.018 
BG 120’ after glucose load, 
mmol/L 
 
0.035 n.s. 
HDL-Cholesterol, mg/dl -0.040 n.s. 
Triglycerides, mg/dl 0.008 0.009 
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6 DISCUSSION 
 
6.1 DISCUSSION (1)  
T2DM and obesity are global health care problems that are closely linked together. The 
concept of diabesity (obesity-T2DM) emerges by the estimation that about 90% of T2DM is 
attributable to weight excess (Hossain P, 2007), and this is the reason because it has been 
applied both in research and clinical settings. The precise mechanisms linking the two 
conditions remain unclear. In recent years an increasing number of works have studied 
common metabolic defects in T2DM and obesity with a particular focus on microvascular 
dysfunction. Indeed, microvasculature plays a central role in glucose homeostasis: an impaired 
capillary recruitment and capillary rarefaction may reduce glucose uptake and contribute to 
insulin resistance development (Levy BI, 2008).  
Expanding AT requires new vasculature to receive an adequate oxygen supply to sustain tissue 
growth both by hypertrophy and by hyperplasia. Several studies suggest that obesity leads to an 
impaired angiogenesis and AT hypoxia, inducing an inflammatory and a profibrotic response 
that plays a pivotal role in the pathogenesis of metabolic complications related to weight gain, 
first of all insulin resistance and diabetes (Corvera S, 2014; Cao Y, 2013; Lee BC, 2014). 
Structural and functional abnormalities, such as lower capillary density (Pasarica M, 2009; 
Gealekman O, 2011), increased adipocyte-capillary distance due to adipocyte hypertrophy 
(Halberg N, 2009) and increased cell O2-consumption (Lee YS, 2014), have been postulated as 
mechanisms leading to AT hypoxia. Furthermore low oxygen tension activates HIF1α pathway 
that, in obesity, is inadequate to sustain the neoagiogenetic response but triggers AT fibrosis 
contributing to a worse metabolic profile (Sung HK, 2013). 
Moreover it is well showed in mice that obesity greatly affects adipose derived stem cells 
(ASCs) behaviour, impairing self renewal and plasticity (Pérez LM, 2013). How diabetes plays 
its role in this settings is widely unexplored. Recent evidences showed an alteration of 
angiogenetic potential and gene expression profile of ASCs in diabetic animals (Ferrer Lorente 
R, 2014; Rennert RC, 2014). All these recent findings highlight the close link between AT, 
microcirculation, angiogenesis and diabetes but utilized animal models or only few human 
subjects without a deep clinical evaluation of metabolic parameters and focusing mainly on 
subcutaneous AT (SAT). From a pathophysiological point of view it is well established that 
dysfunctional visceral AT (VAT) is one of the major determinant of metabolic complications of 
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obesity (Gesta S, 2007) while subcutaneous depots has been considered “metabolically 
healthy”. Nevertheless it could be hypothesized that in the evolution of obesity into diabesity 
,through metabolic impairment, SAT could become dysfunctional as VAT.  
On the basis of these data, we planned to characterize both SAT and VAT  measuring 
adipocytes size, capillary density, ASC and endotelial precursor number, and stromal vascular 
franction (SVF) adipogenic potential,  in lean subjects and in obese patients divided in 3 
groups: Normoglycemic (ob N), prediabetic (pre-T2DM) and Diabetic (T2DM) on the basis of 
clinical and laboratory evaluations. . 
According with the literature (Pasarica M, 2009; Gealekman O, 2011), we found that in SAT 
obese patients had significant decreased in capillary density compared to lean subjects and, 
also in VAT, a depot which has not yet previously investigated in humans, at least to our best 
knowledge. An interesting result to be emphasized is that, while the number of vessels per mm
2 
decreased of 40% between lean and obese SAT, the parallel reduction in VAT resulted higher, 
amounting to 54,5%. This finding supports both the hypotheses that obese AT is less 
vascularized than healthy AT and that SAT, from the point of view of vascularization, is less 
damaged than VAT. Differently from data showed by  S. Corvera’ group we found that VAT has 
a higher number of capillary per mm
2 
both in lean subjects and in obese patients. In contrast to 
our expectations, we did not found any significant differences in capillary density among the 3 
obese patient groups: neither in ob pre-T2DM compared to ob N nor in ob T2DM compared to 
both ob N and ob pre-T2DM (Figure 12).  
Accordingly with these results, the VEGFA expression largely parallel the capillary density 
measured by histological vessel staining, confirming a reduction of vascularization in obesity 
both in SAT than in VAT and failing to shown a worsening effect of the metabolic 
complications and of overt T2DM on vascularization. Instead, we found significant differences 
in adipocyte size. In fact, adipocyte area (μm2) was smaller in lean subjects than in obese 
patients both in SAT than in VAT and, more importantly, adipocyte size had an increasing trend 
in the 3 groups both in SAT and in VAT showing that adipocytes coming from ob T2DM 
patients are the largest ones ( Figure 11). This result is particularly interesting because allow us 
to correlate the adipocyte size with the onset and the development of metabolic complications, 
suggesting that AT is further able to expand by hypertrophy probably generating fat cells more 
and more insulin resistant, independently of patient’s BMI. In fact, as reported in (Table VII), 
ob N and ob T2DM patients selected for histological analysis displayed similar BMI and ob 
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Progressive and continous remodeling
Mature adipocyte
Extracellular matrix Proinflammatory cells
Capillary
Adipocyte area
Capillary density
pre-T2DM had a lower BMI than the other two obese groups. The drawing of Figure 27 well 
recapitulates our findings and represents our pathogenetic hypothesis for diabesity evolution at 
AT level. Moving from an healthy AT, of lean subjects, to an unhealthy AT, of obese patients 
and finally to an metabolic complicated-unhealthy AT, of obese T2DM patients , we observed a 
significant decrease in capillary density only in the first step and a progressive increase in fat 
cell size which characterize all steps analyzed. Regarding the AT vasculature, we have to take 
into account that our observation were only quantitative and we cannot exclude that capillary 
of ob N and of ob T2DM obese patients could differ in perfusion function or angiogenic factors 
responsiveness.  
 
 
Figure 27. Schematic drawing of adipocytes and vasculature remodelling during diabesity. 
 
On the other hands, the findings related to adipocytes are partially in agreement with previous 
report of Lundgren et al. (Lundgren M., 2007) which examined the relationship between fat 
cell size and insulin sensitivity in diabetic and non-diabetic subjects with a wide range of age 
83 
and BMI. This study showed that fat cell enlargement is associated with insulin resistance in 
non-diabetic individuals but not in T2DM subjects. Moreover, we observed that adipocyte area 
positively correlated with IL-6 blood level, underling the relationship between adipocyte 
hypertrophy and inflammation. It is worth noting that our findings are concordant both in SAT 
and in VAT, reinforcing the idea that not only VAT, but also SAT could be dysfunctional. F. H. 
J. Van Tienen and collaborators  (Van Tienen FHJ, 2011) observed that the presence of large 
adipocytes is an indicator of decreased adipogenic potential in SAT and can be the trigger for 
increased macrophage infiltration and inflammatory process activation. 
In fact these authors found that among T2DM subjects, preadipocytes isolated from abdominal 
SAT displayed decreased expression of genes involved in adipogenic differentiation. 
Consistent with these data, our results further showed that adipogenic differentiation 
impairment is already present in a pre-diabetic condition; in fact  SVFs obtained from SAT of 
ob preT2DM and, unless in a minor extent, from ob T2DM displayed a lower adipogenic 
potential in comparison to ob N group (Figure 20). 
More importantly, the ex-vivo quantification of ASCs( CD34+CD45- CD31- cells), Figure 17 
showed that a pre-diabetic condition is sufficient to cause a significant decrease in the ASC, 
that persists also in T2DM obese patients, both in SAT and in VAT. It is interestingly that 
glucose impairment early affects ASCs; this could explain, at least in part, why patients with 
metabolic alterations preferentially expand their AT by hypertrophy than by hyperplasia. ASCs 
isolated from stromal vascular fraction (SVF) of our samples, were lower in lean patients 
compared to obese patients.  
Accordingly with our results, the group of Isakson P. (Isakson, 2009) showed that the number 
of CD133-positive cells, containing pluripotent cells able to differentiate into adipose cell, 
isolated from SAT SVF positively correlate with BMI, suggesting that obese individuals could 
present a differentiation impairment rather than a precursors cells reduction. 
Comparing the two AT depot, we found that VAT is more enriched of ASCs than SAT in all 
obese groups and in lean subjects. Differently, in mice underwent to high fat diet, Joe at al. 
(Joe, 2009),  showed that adipogenic precursors were found eightfold more abundant in SAT 
compared to VAT, consistent with the observation of a prevalent SAT growth by hyperplasia 
and VAT growth by hypertrophy. However recent studies focused on VAT, both in diet-induced 
obese mice (Jeffery, Church et al. 2015) (Wang, Tao et al. 2013) and, more importantly, in 
humans (Arner, Andersson et al. 2013), showed a predominant expansion through hyperplasia 
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rather than hypertrophy, underlying the central role of ASCs in the pathogenesis of obesity in 
both depots.  
As previously reported, we found that the in vitro adipogenic potential of SVF obtained from 
VAT is lower than that obtained from SAT, but this finding was not correlated to the VAT ASCs 
number. It is likely that the VAT microenvironment deeply affects the differentiation capacity 
of ASCs to mature adipocytes. In addition, we found that in obese, but not in lean subjects, 
VAT ASCs display a significantly higher expression of CD105 and CD271 in comparison with 
SAT. The differences of surface marker expression profile of ASCs, could account for a 
differential, depot-specific function, of precursors cells.  
Van Harmelen and colleagues (Van Harmelen V., 2004) found that age correlated negatively 
with proliferation only in SAT preadipocytes and not in the omental depot and he supposed that 
aging has distinct effects on preadipocytes from different fat depots and it could explain the 
loss of SAT and relative preservation of omental fat with aging.  
In our study, even if ob T2DM were older than ob pre T2DM and ob N we did not find any 
correlation between age neither with percentage of ASCs, nor with percentage of mature 
adipocyte cells, after 9 days of culture. Considering the high numbers of samples analysed, we 
can affirm that not age but glucose profile affects both pre-adipocyte and their ability to 
differentiate, certainly in SAT and probably in VAT. 
Moreover, in our study we observed that the number of endothelial precursors cells (EPs), 
defined as CD34+ CD31+ CD45- cells, was higher in SAT of obese patients compared with 
lean subject, whereas in VAT there were no significant differences (Figure 19). Both in SAT 
than in VAT, EPs did not differ in ob pre-T2DM and ob T2DM compared to ob N and this 
underlines that angiogenic potential is lesser affected by glucose impairment than adipogenic 
counterpart, as it was also observed with immunohistochemical analysis.  
In SAT and VAT, EPs showed an opposite trend compared to ASCs; indeed, in obese groups, 
EPs were lower in VAT than in SAT. These results could suggest that VAT expansion is 
achieved preferentially by hypertrophy due to the reduction of the angiogenic potential which 
did not parallel the adipogenic potential represented by the in vivo higher number ASCs in 
comparison with SAT.  
Another interesting result comes from our studies concerning ASCs of obese patients after 
weight loss (ob WL). Consistent with previous data, we found that ASCs are significantly 
higher in ob WL group compared both to obese groups and lean subjects, whereas, EPs are 
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significantly lower in ob WL than the 3 obese groups characterized by different metabolic 
profile. Moreover ob WL group showed a lower PPARγ expression as compared with that of ob 
N and ob pre-T2DM groups. We can supposed that in these patients the relevant WL achieved 
could stimulates the increase of ASCs as a reaction to important fat mass reduction, but the AT 
expansion and hyperplasia are counteracted by the lowering of PPARγ expression and by the 
concomitant limitation of EPs number. Another hypothesis to explain the high percentage of 
ASC quantified in AT of ob WL is that hypertrophic adipocytes, after lipid mobilization due to 
massive WL, could dedifferentiate again into preadipocytes as postulated by Baptista L. et al. 
(Baptista L., 2015), probably through the involvement of pericytes (Silva K., 2015).  
In fact,  a fourfold increase in SAT supra-adventitial cells was described in ex-obese patients 
compared to obese together with an increase in pericytes’s number in both groups compared to 
lean subjects (Silva K., 2015). Many recent studies support the idea that ASCs tend to maintain 
their features even after drastic WL, probably due to epigenetic modulations occurred during 
the obese state, partially explaining the mechanisms involved in weight regain over time. Even 
if microenvironment changes in inflammatory status have been described in SAT after WL due 
to surgical intervention, with a decrease in some cytokines levels, such as IL-6 and C-reactive 
protein, post-bariatric ASCs seem to maintain high levels of other factors such as MCP-1, 
partly sustaining a macrophages tissue infiltration (Silva K., 2015).  
However, the metabolic improvement observed after WL partly depends on the restoration of 
AT from features present before the obesity development. A comparative study of SAT from 
obese, obese underwent to WL due to diet intervention and normal weight subjects suggested 
that a full adipose cell re-programming has been induced after weight loss, with a reduced 
DNA-damage and consequent longer cell survival, an extended replicative lifespan and a 
reduced adipogenic commitment.  
The variables that probably strongly determine adipose cell behavior after WL, causing a 
minimal, partial or complete pre-obesity cell pattern restoration, could be represented by the 
duration of the disease and the presence/absence of obesity-associated comorbidities, which 
contribute to a stabilization of epigenetic modifications and thereby to a cell memory 
reinforcement (Mitterberger MC,. 2014). 
In conclusion, our study, confirmed that obese AT is less vascularized than lean AT and showed 
for the first time that T2DM does not represent an aggravating factor to the vascular reduction 
already present in obesity. On the contrary T2DM and also prediabetic condition are able to 
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further modify the AT architecture, remodeling the mature adipocyte size and the adipogenic 
potential mediated by ASCs importantly reducing the AT hyperplastic growth capacity. Our 
results allow us to assume that the primum movens in the diabesity evolution at AT level has to 
be searched more in the adipocyte/preadipocytes remodeling than in the 
vasculature/angiogenesis impairment and that both depots, SAT and VAT, equally play a pivotal 
role in the metabolic disease progression. 
 
6.2 DISCUSSION (2)  
Hypoglycemic events are a well-established complication of upper gastro-intestinal surgery. In 
particular is well known that the frequency of asymptomatic hypoglycemia after RYGB may be 
over 30% (Service GJ., 2005). Similar outcomes are reported for LSG in only two studies 
(Papamargaritis D., 2012; Natoudi M., 2014) in a small number of patients and little none is 
known about clinical predictors.  In our study we aimed to identify how many subjects develop 
hypoglycemia after LSG and if we can find any predictors of these events before surgery in 
non-diabetic obese patients.  
We observed that 5 of 197 (2, 5%) patients, have experienced at least one severe hypoglycemic 
event (BG ≤ 2.7 mmol/L) during 3 hour OGTT before bariatric surgery. This data is consistent 
with data present in literature for obese patients where hyperinsulinemic hypoglycemia is 
described (Pigeyre M., 2015).  
After LSG, 61 of 186 (32, 8%) patients have experienced at least one hypoglycemic episode 
during OGTT. These data are just partly comparable with the results reported by 
Papamargaritis and Natoudi (Papamargarits D., 2012; Natoudi M., 2014) because both authors 
had subjected patients to a 2 hour OGTT and have found 4 of 12 (33%) patients with BG ≤ 3, 3 
mmol/L at 90 or 120 minutes after glucose load and 6 of 30 (37, 5%) patients with BG ≤ 3, 3 
mmol/L at 90 or 120 minutes, respectively. In our study the highest frequency of severe 
hypoglycemic events were observed 150’ after OGTT, in 20,2% of subjects, while, at 90' and 
120' minutes after glucose load, 2,8% and 11,7% of our patients have had a  hypoglycemic 
events.  
In our recent study (Nannipieri M., 2016), we demonstrated that all patients with 
neuroglycopenic symptoms had, at least one value of blood glucose level ≤ 2, 7 mmol/L during 
OGTT. Certainly, OGTT overestimates hypoglycemic events but, considering a lower cut-off 
of hypoglycemia compared to other studies (2,7 mmol/L vs 3,3 mmol/L), and,  considering the 
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large number of patients included in this study, we can  affirmed that hypoglycemia is a 
common complication one year after LSG. Moreover, even if we didn't any specific test in 
order to quantify the number of patients reporting hypoglycemic symptoms under free-living 
conditions, after blood exams, all patients did a medical interview, and, about one third of our 
patients have reported  symptoms consistent with hypoglycemia, in particular, headache, 
dizziness, irritability and sweating. Most of symptomatic patients were those who, during 
OGTT, had blood glucose levels ≤ 2, 7 mmol/L; indeed, only 4 patients who reported 
symptoms consistent with hypoglycemia had, during OGTT, glucose levels > 2, 7 mmol/L. 
Therefore, we can conclude that mild hypoglycemia after OGTT does not reflect the real 
clinical status and we can suggest that OGTT could be a good diagnostic test if carried out over 
3 hours and if the diagnostic threshold for hypoglycemia is lowered at 2.7 mmol/L. 
Moreover, several studies described an early dumping syndrome after RYGB ( Hamer H.F., 
2012); even if we didn’t apply any questionnaire for dumping, we find hypoglycemia later than 
one hour and it could be explain because in LSG the pyloric valve and the duodenal feedback 
inhibition of gastric empting are preserved.  
These two anatomical differences in LSG could slow down gastric empting and so avoid the 
typical symptoms of early dumping syndrome. Recently, Lee Clare J (Lee CJ., 2015) on the 
basis  of validate questionnaires, demonstrated that RYGB confers some increased risk 
between  the presence  of hypoglycemia symptoms before and after surgery while these risk 
was not find in subjects underwent to LSG. So we can think that LSG could be seen as a good 
potential alternative. Moreover, these findings are according with Papamargaritis work that 
demonstrated an increase of late dumping symptoms at 6 and 12 months after LSG. 
Another aim of our study was to analyze the differences in clinical and metabolic 
characteristics between non diabetic morbidly obese patients who developed or not post-OGTT 
hypoglycaemia one year after LSG. According with the recent work of Papamagaritis 
(Papamergaritis D., 2016) performed on 18 non diabetic obese patients six month after LSG, 
we found that patients experienced hypoglycemia had a greater weight loss and a greater 
reduction in waist compared with NHip patients (Table XVI).  
After bariatric surgery, an increase risk of traumatic deaths and an increase in depression have 
been described in patients with hypoglycemia. In rare cases, pancreasectomy for untreatable 
severe hypoglycemia has been required years after RYGB. For these reasons, it is very 
important to identify patients at high risk of hypoglycemia in order to educate them to 
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recognize symptoms and to use adequate nutritional habits. Our findings highlight that patients 
with greater weight loss and lower BMI after surgery have a higher risk to develop 
hypoglycemic events after surgery, but the identification of baseline pre-operative predictors 
remains elusive. In fact, even if in our study we found that baseline younger age, lower fasting 
blood glucose and higher triglycerides have been shown to be independent predictors of 
hypoglycemia after surgery, their predictive power is really small.  
The identification of more reliable predictors would require a more extensive investigation of 
the pathophysiological events leading to the development of hypoglycemia after LSG.  As we 
described in our recent, in a smaller group of patients (Nannipieri M., Belligoli A., 2016), in all 
subjects, LSG anticipated the time of post-OGTT glucose peak and lowered the plasma glucose 
nadir through more rapid dumping of gastric contents into the small bowel.  In the Hip 
subjects, however, the features predisposing to hypoglycemia were accentuated as compared 
with NHip subjects.  The relative potency of these factors probably varies among subjects and 
is difficult to gauge.  Firstly, post prandial hypoglycemia (PPHG) may be detected beyond the 
time frame of the current study.  
Secondly, in some individuals a lesser weight loss might protect against PPHG despite a high 
load of predisposing factors; in yet other subjects, gastrointestinal hormone release or action 
may be defective or pre-existing insulin sensitivity be impaired.  Thirdly, gastric emptying may 
change over time because of long-term adaptations of motility or ensuing autonomic 
neuropathy (e.g., long-term and/or uncontrolled diabetes).  Finally, the pattern of predisposing 
factors may differ depending on whether PPHG manifests itself only once or repeatedly and 
whether it is mild-moderate or severe. Additional factors that were not measured in our study 
might have had a part.  
For example, (1) lack of reduction of ß–cell mass, which was constitutively increased during 
the obese state prior to surgery, (2) gut hormonal activation of new ß-cell formation due to 
surgically induced changes in the secretion of insulinotropic incretins, or other regulatory 
peptides, (3) abnormal counterregulatory hormonal responses, (4) changes in gut microbiota, 
and (5) changes in bile acid composition. 
In conclusion, these findings confirm a high incidence of severe hypoglycemia after a 
provocative test (OGTT) 1-year after LSG. Patients with hypoglycemic events have a lower 
weight and BMI and a greater %EBML after LSG. Hypoglycemia is more frequent in patients 
having lower age, lower fasting blood glucose levels, and higher triglycerides levels before 
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LSG but these predictors do not have such a marked correlation to contraindicate LSG.  
Whether hypoglycemic events are so frequent in daily life of patients underwent LSG as shown 
by OGTT is something that needs a deep investigate and we need to deep investigate also the 
pathophysiological events leading to the development of hypoglycemia after LSG. 
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